experience patients telling stories scan marked images xtend app watch videos annual report experience adeline telling story scan image xtend app watch video every day developing cures patientsas science driven organisation strive towards converting todays knowledge tomorrows therapies pushing boundaries millions people like adeline hepatitis b developing medicines help themeverywhere bringing products patientswe committed bringing medicines tests rapidly sustainably need open new ideas working collaboration healthcare systems partners key resolving critical access barriers therapieseveryone benefiting people needmotivated skilled employees collaborate across cultures locations develop lifesaving products share one purpose abiding dedication high quality ensures doctors backing pioneering science treat patientsdoing patients need nextwe believe urgent deliver medical solutions right noweven develop innovations future passionate transforming patients lives courageous decision action believe good business means better world come work day commit scientific rigour unassailable ethics access medical innovations today build better tomorrow proud many working one across functions across companies across world rochei feel able strengthen patients position stakeholder ike de rooijvan haaren consultant oman moved basel five years ago husband numbers always asked meant three sons months later diagnosed individual patients herpositive breast cancer fortunately received timely treatment two roches breast project meant last three months cancer medicines native holland team realised could benefit leave young boys husband behind journey reallife experiences patient new place therefore signed patient consultant contract continued work roche made mind still undergoing treatment three years wanted give something back roche company kindly allowed participate live middle east sometimes study one medicines inspired poses logistical challenge technology helps greatly mentioned friend worked try attend meetings person possible work roche came back details broader franchise team days project aimed putting patient one years involved prelaunch brand teams see effect would launch postlaunch activities role give would change decisionmaking within patient perspective stage medicines team life cycle also member committee set roche along patients review nervous first decided take plunge topics teams request advice patient realised share information materials clinical trials experiences took couple meetings brand team get used team got feel able strengthen patients work working breast cancer position stakeholder difficult medicine treated engage patients times makes hard curious hear experience therefore felt understand real needs efforts confident share opinions beginning one involved business teams really could see impact actual patients looking ways give important stakeholder voice room never interested stronger voice work experience ike telling story scan images xtend app watch videoinnovationits dna always worked across disciplines geographies drive scientific discovery redefine possible improve patients lives working understanding diseases differ also world leader vitro diagnostics molecular level develop new business track record allows us build lasting tests medicines prevent diagnose treat meaningful partnerships across world diseases bring patients need research academia public healthcare institutions combined strengths diagnostics pharmaceuticals personalised healthcare founding families continue hold majority strategy aims fit right treatment right voting stake company stability allows patient tradition sustainable thinking learn setbacks focus lasting value patients worlds largest biotech company develop society remain dedicated highest breakthrough medicines improving standard standards quality safety integrity legacy care across oncology immunology infectious based respect individual well diseases ophthalmology neuroscience communities world live inexperience roche scan world map xtend app watch video key figures highlights chf million driving growth group sales chf billion incremental sales medicines launched since drive growth rejuvenation product portfolio chf million read core operating profit treating rare cancer chf rozlytrek approved treat rare form lung cancer occurs patients dividend read chf million launching cobas pro r core investments nextgeneration integrated serum work area solutions improve efficiency shorten results delivery million patients read treated roche medicines contributing sustainability roche medicines roche ranked amongst sustainable healthcare companies dow jones model list essential medicines sustainability indices employees worldwide north america europe employees employees genentech south san francisco us basel kaiseraugst rotkreuz switzerland roche diagnostics indianapolis us mannheim penzberg germany latin america asia employees employees chugai tokyo japan africa shanghai suzhou china employees australianew zealand employees research development sites manufacturing sites pharmaceuticals pharmaceuticals diagnostics worldwide diagnostics worldwide roche group headquarters manufacturing sites pharmaceuticals diagnostics largest sites based number employees sales sites pharmaceuticals diagnostics research development sites pharmaceuticals diagnostics growth rates report constant exchange rates cer average number employees expressed fulltime equivalents overview environment business performance community engagement science innovation integrity business access healthcare corporate governance people remuneration report material topic covered chapter cybersecurity reporting approach roche committed transparent reporting endeavour drive economic social environmental performance diligence financial performance reporting scope boundaries material risks opportunities discussed financial non financial reporting consists annually corporate executive committee annual report finance report reviewed audit committee board online report contains annual financial directors board directors statements consolidated financial statements effectiveness group risk management process non financial performance indicators covers regularly monitored group risk advisory regions divisions roche group team overall process reviewed externally january december financial appropriate risk management embedded reporting scope defined outlined levels group pharmaceuticals finance report significant diagnostics divisions global functions conduct changes scope compared formal risk assessment process least year must develop mitigation plans gri standards materiality material risks followed gri g guidelines global reporting initiative since transitioned read corporate governance gri standards using gri guidelines disclose critical impacts also identify longterm business sustainability activities environment society trends associated risks opportunities economy respect conducted first annual basis integrate existing materiality analysis corporate level group risk management process year emerging conducted second global materiality trends including associated risks opportunities assessment including expert interviews feedback identified internal external sources stakeholders results based findings corporate sustainability www assessment featured pages committee prioritises selects top business report report also published website see sustainability trends among identified trends arrochecom link technological transformation rising cyber rochecomarepdf dependency rochecomfbepdf risk management risk management policy sets roches un sustainable development goals risk management approach identifying analysing managing support united nations sustainable rochecomrisk reporting internal external risks opportunities development goals sdgs within sphere management consolidated group risk report covers corporate business strategy contribute toour reporting approach roche business sustainability trends number sdgs particularly pleased see dedicated goal health sdg technological transformation goal closely connected achievement digital evolution external world helps drive universal health coverage goes hand technological transformation roche allows us hand better access quality essential medicines develop effective tailored solutions healthcare diagnostics fits perfectly vision create new markets digital growth network improve save lives since sdgs mandate safeguard compliance integral part annual reporting time accelerate enable digital innovation across examples contribution un goals organisation roche digital registry provides listed un sdg webpage see link live database digital channels ecosystem helps ensuring compliance transparency efficiency addition risks associated technological external assurance transformation assessed managed nonfinancial reporting verified group risk management process independent third party pricewaterhousecoopers ag pwc focused materiality determination rising cyber dependency process design sustainability risks era cybersecurity threats constantly opportunities determination process rise committed security enhancements figures areas safety security health personal privacy protection roche initiated bug environmental protection people contributions bounty programme partner global roche strengthened control framework review hacker community identify relevant security procedures reporting aspects terms issues exploited nonauthorised external contributions healthcare patient organisations users addition data privacy aspect included example new roche directive roche supplier code conduct ensure proper developed communicated respective use confidential information third parties internal stakeholders result figures related grants donations sponsorships healthcare patient organisations subject reasonable assurance performed pwc limited assurance procedures prior years see independent assurance report materiality assessment stakeholder engagement engaging stakeholders essential build trust understanding expectations embedding feedback strategy daily business able jointly address common issues develop longterm solutions order identify topics particularly institutions peers suppliers contract research relevant roche stakeholders society organisations universities investors large deliver lasting shared value conducted collected external internal stakeholder indepth materiality assessment corporate level views via online survey identify among key stakeholders built important pressing issues roche first materiality analysis conducted address next three five years added external perspective gaining critical insights important final step analysed various insights stakeholders consider emerging identified material topics stood trends topics highly relevant us key stakeholders properly address topics aligned approach current goals measuring approach materiality assessment performance defined set indicators integratedbuilding group risk management processand inclusive designed collaboratively addition materiality assessment www colleagues across multiple functions risk shared internally functions charge materiality advisory human resources investor relations managing respective topics also informed rochecommateriality compliance finance safety security health discussion define new corporate goals environmental protection well subsequent sustainability objectives key performance communications communications priorities rolled indicators finally outcomes materiality rochecom took outcomes group risk assessment fed back performance management process starting point identify group risk management process key emerging trends relevance roche contribution group conducted qualitative interviews process results materiality un sdgs experts across broad stakeholder analysis endorsed roche corporate rochecomunsdgs categories including patient organisations global sustainability committeemateriality roche material topics committed delivering sustainable value stakeholders addressing following material topics commitment performance material topics supporting un sdgs innovating patients million patients treated sustainable healthcare systems committed developing medicines roche medicines availability healthcare diagnostics significantly improve billion tests conducted affordability healthcare peoples lives delivering rapid roche diagnostics products personalised healthcare broad sustainable patient access btds breakthrough therapy realworld data products designation awarded fda patient centricity since rd efficiency roche medicines preparedness aging society model list essential medicines product safety product quality trustworthy partner new partnerships human rights committed establishing mutually pharmaceuticals diagnostics ethics transparency beneficial longterm relationships partner choice according compliance partners thirdparty surveys product safety supplier critical issue product quality discontinued based audit results cybersecurity grievances human rights data privacy impacts filed addressed resolved realworld data formal grievance mechanism providing great workplace women key leadership roles talent attraction retention committed providing work key leaders diverse work organisational agility environment employees experience preparedness aging society encouraged build careers employee engagement pursue passions protecting environment improvement ecobalance energy efficiency committed minimising since longterm mindset environmental impact operations decrease energy consumption use products per employee since decrease general waste per employee since delivering continued growth group sales longterm mindset committed creating value core operating profit continuously stakeholders sales invested rd achieving sustainable high profitability growth rates report constant exchange rates cer average focus leadership fitting treatments patients inspiring outcomes matter distinctiveness ways working excellence science agile networked delivery setup value stakeholders built innovationour strategy roche strategy focus finding new medicines diagnostics help patients live longer better lives evolve practice medicine guided purpose pharmaceuticals diagnostics capabilities patients need next diversity approaches maximise innovation company year history longterm orientation advancing field medicine bringing novel treatments diagnostics patients patient delivery create value remain core reason stakeholders partner choice bringing come work every day significant medical benefit patients doctors payers offering great place work employees delivering sustainable positive contribution society earning competitive returns investors focus fitting treatments patients providing right therapy group people respond best right time right value inhouse combination pharmaceuticals diagnostics uniquely positioned ultimately takes people integrity courage deliver personalised healthcare developing passion make difference patients internal capabilities building strategic people proud say roche partnerships ready next stage personalised leadership inspires outcomes matter healthcare combine insights multiple data embracing diversity inclusion different sources sophisticated analytics drive backgrounds perspectives experiences across effective efficient research allow better entire organisation foster innovative solutions therapeutic decisions patients access benefit patients products also critical part strategy detailed access plans embedded business ways working enable agile networked local level responses everincreasing pace change balancing needs stability speed flexibility continue concentrate energies entirely prescription medicines vitro diagnostics setup built innovation autonomous rather diversify sectors like generics research development centres alliances biosimilars overthecounter medicines external partners foster diversity scientific approaches agility global pursuit excellence science geographical scale reach enables us attract distinctiveness rests four key elements talent leading global science clusters exceptionally broad deep understanding bring diagnostics medicines quickly disease biology seamless integration people need dear shareholders continued make significant progress efforts use outstanding scientific achievements give people better quality life help lead healthy lives demand recently launched medicines intend use partnershipbased approach multiple sclerosis ocrevus haemophilia help resolve challenges facing healthcare hemlibra particularly high system mean partnering research goes cancer immunotherapy tecentriq laboratories patient organisations biotech three products major contributors roche companies also authorities example groups impressive sales growth signed framework agreement croatian chf billion government view providing personalised cancer treatment approximately approval targeted cancer treatment people country diagnosed rozlytrek genomic test enabled us open disease annually globally roche working new chapter development personalised many partners deliver better care patients healthcare new medicine effective tumours exhibit two relatively rare progress made oncology also genetic changes accurate pretreatment diagnosis therapeutic areas thus able submit essential one roches biggest core dossiers two new medicines second half competencies really comes ability year risdiplam hereditary disorder spinal combine diagnostic procedures data clinical muscular atrophy satralizumab specific practice medicines brings us closer goal disease central nervous system finding personalised treatment options many new active ingredients bring hope people patients possible eventually offering even rare severely debilitating diseases risdiplam effective treatment options alleviate us food drug administration fda granted peoples symptoms best case help priority review satralizumab breakthrough make full recovery disease therapy designationchairmans shareholder letter roche gene therapies particularly promising roches innovativeness also reflected net number rare diseases directly address income ifrs rose substantial genetic cause conditions therefore chf billion view strong intend bolster presence substantially business performance proposing area expanding portfolio therapeutic active dividend chf per share nonvoting ingredients acquisition us gene equity security annual general meeting therapy company spark therapeutics march subject approval rd consecutive dividend increase however innovation lifeimproving medicines come price interview pages thanks successful new launches firstclass severin schwan ceo roche group discusses development portfolio confident roche added value new treatments offer continue growth trajectory despite patients potential generating economic important medicines going patent benefits healthcare system overall would like thank partners trust despite progress medicine global demand cooperation roche group employees stateoftheart diagnostics personalised tireless commitment patient wellbeing treatments remains huge therefore invested offer shareholders heartfelt thanks chf billion research development last trust placed us affinity year intend maintain record level company investment industry gratifying note fda sufficiently persuaded clinical benefits four roche medicines award breakthrough therapy designations bringing total since achievement expression least value new products dr christoph franz represent patients society chairman board directors roche board directors december paul bulcke b e g prof sir john bell e g dr christoph franz chairman c e g anita hauser e g bernard poussot c e g dr andreas oeri representative shareholder group pooled voting rights e g andr hoffmann vicechairman representative shareholder group pooled voting rights c e g dr severin schwan f dr claudia suessmuth dyckerhoff b e g julie brown b e g prof dr richard p lifton c e g prof dr hans clevers b e g corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director g independent member board directors committee chairperson growth rates report constant exchange rates cer average important thing medicines exist severin schwan ceo roche group talks blessings new medicines prices emotional moments work perhaps heard baby pia nine affordability switzerland people spend monthold girl belgium spinal muscular alcohol tobacco medicines atrophy sma mother financed treatment extremely expensive gene therapy via crowd however charging millions gene therapy funding would say world something justifiable like happened roche medicine gene therapy new field unlike conventional first think commitment shown pias mother therapies treatment targets roots wonderful important thing disorder remedies causefor lifetime medicines help daughter exist best casewith single injection remember well spending time swiss current billing procedures huge sum due one patients organisation sma years ago fell swoop need new financing time absolutely options sma solutions firmly believe need form risk many parents lost children young sharing health insurers pharmaceutical age see far cometwo drugs companies health insurers would pay treat sma already market treatment several years cases coming soonthen huge blessing families long medicine proven effective way financial expenditure would blessing affected access linked closely benefits therapy medicines patients would guaranteed access yes question access crucial first foremost requires functioning insurance system contribution roche making keep make regular contributions medicines affordable medical care guaranteed patients look surveys united states today affected unfortunate cases developed people believe medicines make countries question social solidarity health costs actually similarinterview ceo roche group roche story switzerland many people assume theme years annual report health insurance contributions rising patient centre mean medicines medicines actually make far lower personally percentage overall costs today benchmark everything ten years ago simply reducing prices would certainly every decision ask patients interests hardly benefit patients long run company would take considerable financial risk order keep investing new medicines talk patients hear therefore important contribution frequently continuing invest research development gratitude talking patients many taking risks develop new better drugs alive roche developed first place particular drugs predominantly gratitude gives added motivation people emerging developing countries simply afford medicines rational person moments achieved pioneering work field work also affect emotionally differential pricing means tailor prices might email acquaintance purchasing power country question treated successfully one using model possible expand access medicines vital cancer drugs massively china example also countries infrastructure like letter patient thanked completely lacking hardly life hospitals doctors laboratories countries yes patient treated cancer drug thinking goes beyond medicines work alecensa received letter behalf local partners lay foundations reasonably roche employees think proud functioning basic healthcare constantly impressed accomplishing work employees achieve field roche corporate executive committee december dr james h sabry global head pharma partnering dr william pao head roche pharma research early development pred dr alan hippe chief financial officer cristina wilbur head group human resources dr severin schwan ceo roche group bill anderson ceo roche pharmaceuticals dr gottlieb keller general counsel dr michael varney head genentech research early development gred barbara schdler head group communications dr thomas schinecker ceo roche diagnostics member enlarged corporate executive committee sustainable development goalbusiness performance roche business performance new products drive performance roche group dedicated longterm success new product approvals strong flow positive data clinical studies demonstrate high quality pipeline material topic covered chapter longterm mindset strong results roche group significant increase number people treated new products basis strong performance group sales rose chf billion lower sales herceptin mabthera core eps grew ahead sales core rituxan operating profit increased reflecting strong underlying business performance ifrs net income growth japan also driven recently increased due impact lower impairments launched products despite considerable competition intangible assets compared biosimilars continued strong uptake new medicines international region sales grew mainly successful product launches new disease areas driven significant increase number provide important new treatment options patients benefiting roche cancer drugs people severe diseases chronic conditions china strong sales herceptin avastin result sales pharmaceuticals division abtherarituxan increased chf billion key growth drivers multiple sclerosis medicine ocrevus diagnostics division sales increased new haemophilia medicine hemlibra chf billion business area centralised cancer medicines tecentriq perjeta strong point care solutions main contributor uptake medicines introduced since generated growth driven immunodiagnostics chf billion growth offsetting business growth reported asiapacific impact competition biosimilars latin america emea north mabtherarituxan herceptin europe japan america sales stable decline combined chf billion mabthera rituxan herceptin avastin us estimated pharmaceuticals key drug approvals decline chf billion us fda granted additional approvals medicines already commercially available us sales increased led ocrevus two new cancer therapies hemlibra tecentriq ocrevus sales driven tecentriq combination therapy initial treatment demand new returning patients metastatic nonsquamous nonsmall cell lung first biosimilar versions mabtherarituxan cancer nsclc herceptin avastin launched market tecentriq combination therapy extensivestage later year small cell lung cancer essclc tecentriq combination therapy triplenegative europe sales stabilised strong demand breast cancer companion diagnostic test new medicines including ocrevus perjeta tecentriq herceptin hylecta subcutaneous injection alecensa hemlibra able offset impact treatment breast cancerbusiness performance roche kadcyla adjuvant treatment herpositive early breast cancer new cancer medicines rozlytrek lung cancer specific gene mutation solid tumours carrying certain gene fusion well polivy previously treated aggressive lymphoma authorities eu approved hemlibra people severe haemophilia without factor viii inhibitors tecentriq combination therapies initial treatment form lung cancer certain type breast cancer initial treatment nsclc small cell lung cancer quality expert roche production unit conducts one multiple checks medicines ensure respective production criteria met japan rozlytrek approved treatment ntrkpositive tumours diagnostics nextgeneration systems tests fda cleared cobas pro integrated solutions new generation serum work area clinical global access program expanded beyond chemistry immunochemistry laboratory solution hiv include tests mycobacterium tuberculosis designed optimise laboratory operations mtb hepatitis b c hbv hcv cobas pro integrated solutions laboratories human papillomavirus hpv low middle able run tests faster less equipment automate income country programmes disease manual tasks deliver results quickly aid burden highest expansion global treatment decisions access program highlights roches commitment towards making costeffective resources easily fda approved ventana pdl sp assay available many people contributing first companion diagnostic test help identify elimination diseases regions triplenegative breast cancer tnbc patients eligible greatest need treatment tecentriq plus chemotherapy outlook roche launched ventana dual ish dna sales expected grow low midsingle probe cocktail companion diagnostic test breast digit range constant exchange rates core earnings gastric cancer patients eligible targeted therapy per share targeted grow broadly line herhuman epidermal growth factor receptor sales constant exchange rates roche expects important biomarker breast gastric cancers increase dividend swiss francs growth rates report constant exchange rates cer average emea europe middle east africa immunodiagnostics driving divisional performance integrated solutions broad test portfolio support precise fast treatment decisions thus benefiting patient diagnostics division continued increase sales instrument sales due shipment delays regionally growth chf billion decline sales led north america asiapacific sales increased china centralised point care solutions main growth market increase sales business area major contributor divisional performance growth diabetes care sales increased driven primarily driven immunodiagnostics north america sales growth mainly came business due instrument launches accuchek guide product line ongoing rollouts mainly china us south korea sales growth partially offset decline instruments solutions roche coagulation monitoring north america diagnostics business improving standard patient care means extending clinical use molecular diagnostics overall sales increased current tests developing new algorithms growth underlying molecular business means investing breakthrough clinical studies growth driven blood screening well digital solutions clinical decision support sequencing business regional growth led asiapacific mainly china emea setting new standards precision medicine roche diagnostics maintained industryleading tissue diagnostics sales stable higher position continuing bring market advanced sales advanced staining reagents offset lower integrated solutions diagnostic testing laboratory efficiency clinical decision support diabetes management cobas pro integrated diagnostic solutions provide designed meet challenges today even anticipate needs tomorrow also simplify shortens delivery time results complexity laboratory professionals physicians patients across therapeutic healthcare organisations face every day helping improve patient outcomes rapidly changing areas support clinical decisionmaking healthcare environmentbusiness performance roche topselling product portfolios chf millions cobas immunodiagnostics cobas clinical chemistry ventana advanced staining cobas blood screening accuchek diabetes care cobas systems tests help speed treatment decisions reduce spread infectious diseases cause deaths worldwide significantly expanded range assays also may roche launched new tests integrated core lab several launches cobas systems help speed treatment approvals broad portfoliothe industrys reduce spread tuberculosis leading comprehensiveenables clinical decisionmaking cause infectious disease deaths worldwide personalised healthcare launch cobas mtb cobas mai tests countries accepting cemark accelerated may fda granted k clearance tuberculosis diagnosis treatment detecting cobas tvmg test use cobas antimicrobial resistance high sensitivity systems addition cobas tvmg test cobas mtb test enables increased detection testing menu provides flexibility process tuberculosis challenging smearnegative samples four sexually transmitted infections one patient complete mycobacteria test menu provides sample chlamydia trachomatis ct neisseria flexibility detect combination tuberculosis gonorrhoeae ng trichomonas vaginalis tv drugresistant tuberculosis nontuberculous mycoplasma genitalium mg mycobacteria infections single patient sample growth rates report constant exchange rates cer average month launched ventana ros also important approvals companion sp rabbit monoclonal primary antibody diagnostics march ventana pdl sp globally first vitro diagnostic ros assay gained fda approval first companion immunohistochemistry ihc assay test detects diagnostic identify triplenegative breast cancer presence ros protein tissue may patients eligible treatment tecentriq useful identifying rospositive cancer cases abraxane celgene assay launched guidelines college american pathologists ce markets august ventana pdl sp national comprehensive cancer network assay developed enhance visual contrast recommend ros testing confirmed lung tumourinfiltrating immune cell staining adenocarcinoma cases ros also studied triplenegative breast cancer pdl primarily number clinical trials cancer types expressed cells rather tumour cells assay primary diagnostic improving lab efficiency quality control assay tecentriq clinical development information sharing key benefits integrated programme tecentriq see core lab april released cobas infinity proven global lab software solution new april launched ventana dual ish features cobas infinity lab software solutions dna probe cocktail companion diagnostic test already installed countrieshelp ceivd countries breast gastric cancer laboratories integrate wide range processes patients eligible targeted therapy ordering diagnostic tests actual test results important biomarker found breast gastric new cobas mobile solution offer customers cancers new assay helps drive personalised modern tablet solution interact instrument healthcare quickly delivering critical information boost efficiency convenience using treatment options mobile apps cobas mobicheck cobas screen share user assistance roche dialog cobas september fda approved cobas babesia mobile solution continuously enhanced test use cobas systems extended meet current future customer demands individual blood donation testing use whole blood important innovation september fda cleared cobas pro babesia parasite lives red blood cells integrated solutions new generation serum detected traditional plasma serum samples work area solutions already launched approval roches first wholeblood assay january countries accepting ce mark helps healthcare professionals diminish potential improve efficiency allows tests per risks infection transfused blood products hour three synchronised modules working wholeblood testing paves way even safer parallel cobas pro shortens delivery time blood supply exposing previously undetectable results physicians patients across therapeutic red blood cellbased pathogens like babesia areas support clinical decisionmakingbusiness performance roche experience advantages modern diagnosis scan images xtend app watch video immunocompromised transplant patients benefit digital transformation gains momentum cobas ebv bkv tests also launched approach data healthcare digitalisation september countries accepting ce mark extends well beyond technology automation new tests run cobas systems digitalisation integration taking diagnostics healthcare professionals determine beyond lab beyond would transplant patients risk complications possible years ago caused reactivation epsteinbarr ebv bk viruses systems tests software solutionsour integrated core lab helps laboratories improve efficiency quality controls information sharing thereby supports physicians patients treatment decisions january launched upath enterprise software board opening patient case app digital pathology offering new standard identifies appropriate guidelines based personalisation pathology workflows upath patients cancer type clinicians select enterprise software enhances user experience intended pathway easily click digitised drastically decreasing imagerendering times decision tree flowchart personalise individual integrating automated image analysis improving steps specific patient pathway accessible efficiency improved workflow sharing tumour board participants exported cases pathologists upath launch follows emr electronic medical record system sent release ventana dp digital slide patients submitted reimbursement approval scanner payers digital tools help convert vast amounts roche ge healthcare partnership healthcare data actionable insights navify exemplifies collaborative approach combining clinical decision support portfolio continues complementary expertise advance patient care grow strengthen march announced partnerships playing key role driving ce mark navify mutation profiler clinical future precision medicine creating software annotation interpretation clinical comprehensive datadriven healthcare ecosystem reporting nextgeneration sequencing ngs tests launched navify mutation improving infectious disease testing access profiler navify therapy matcher optional global access program major clinical support aid helps clinicians linking positive impact diagnosing treating helping clinically actionable mutations relevant therapy reduce spread hiv low middle options income countries positive impact hiv diagnostics continues grow january may roche ge healthcare launched added two new sample types utilisation navify tumor board first collaboration cobas system product partnership incorporating medical image viewing storage capabilities july expanded programme patient data enables tumour boards includes molecular diagnostics hiv viral load comprehensive view patient hiv hiv early infant diagnosis cobas plasma separation card mtb mtbrifinh october released navify guidelines new hepatitis b c human papillomavirus app navify decision support portfolio assays run cobas app embeds latest national comprehensive platforms various testing volume needs see cancer network clinical practice guidelines access chapter information oncology nccn guidelines covering four roche initiatives increase access lifesaving common cancers within navify tumor diagnostics medicinesbusiness performance roche cobas plasma separation card supports diagnosis infections several viruses bacteria card designed simplify blood collection spanning early infants adults sample transportation connections count blood glucose range taking picture diabetes care portfolio offers collaborative accuchek active strip smartphone integrated personalised approach aims determine optimal therapy person february expanded collaboration diabetes risk developing disease agreement senseonics distribution eversense xl insertable continuous glucose march launched accuchek smart pix online monitoring cgm sensor additional markets spain portugal launches europe latin america asiapacific countries planned successor region june marked placement smart pix software allows management th eversense xl sensor working multiple patients within single digital diabetes mysugr mobile diabetes management app eversense solution open connectivity xl measure glucose values days noninsulindependent people type tubeless accuchek solo micropump system diabetes cemarked accuchek sugarview fully integrated accuchek portfolio enables meterfree glucose monitoring launched nine markets argentina australia launched pilot project mexico austria italy kuwait poland spain switzerland philippines nigeria first app displays united kingdombusiness performance roche women babies good fortune maria schoedl roche germany work roche diagnostics penzberg might different story diagnostic preeclampsia one focus areas work tests markers already available fate probably even ironic shortly afternoon blood pressure first shot birth daughter seven preeclampsia diagnosis could made diagnosed severe form condition well much earlier necessary steps could actually diagnosed given understanding taken avoid onset disease preeclampsia work doctors mediumsized perinatal centre suspect time leading large clinical trial anything condition turned critical validating two diagnostic tests shortterm prediction preeclampsia benefit fortunately daughter delivered caesarean measures women suspected began display serious symptoms disorder tested arrived clinic escaped unscathed lucky could applying specific criteria helpful tool easily suffered brain haemorrhage even identify patients high risk developing liver failure stage severe eclampsia disease need monitored common outcomes women closely also enables clinicians rule babies good fortune preeclampsia women otherwise showed symptoms condition day daughter delivered remember blood pressure spiked high levels husband knew wanted doctors however concerned another child acutely aware put csection later evening things developed preeclampsia first pregnancy started spiralling control began meant highrisk patient reassured serious visual disturbances could hardly see fact better tests available still managed express suspicion told immense relief especially second doctor could suffering serious form pregnancy went specialised university hospital preeclampsia lost consciousness already tested markers actually started seizures doctors benefited new roche tests developed got really worried also rule happily son born without complications complications like cerebral bleed five years ago continued demand new medicines increasing number patients benefit innovations based roches legacy medicines new disease areas uptake newly introduced medicines breast cancer strong sales growth reported continues strong contributing almost regions us new indications growth sales pharmaceuticals division extensivestage small cell lung cancer triple increased chf billion negative breast cancer drove sales growth new medicineskey growth drivers kadcyla first approved chf billion ocrevus first approved chf billion treating herpositive breast cancer treatment relapsing increased demand kadcyla driven rms primary progressive ppms forms us international region supported multiple sclerosis ms people use treating patients residual disease treated ocrevus globally clinical surgery trial realworld settings data continue show consistent favourable benefitrisk profile hemlibra first approved chf billion strong demand treatment indications treating people haemophilia continued addition sales increases factor viii inhibitors also approved us growth supported launches treat people haemophilia without factor viii international markets inhibitors hemlibra prophylactic treatment administered subcutaneously perjeta first approved chf billion multiple dosing options weekly every two therapy herpositive breast cancer weeks every four weeks uptake sales grew strongly regions increased strong us japan europe patient demand perjeta adjuvant early breast cancer therapy supports continued esbriet first approved chf billion strong growth idiopathic pulmonary fibrosis sales continued expand driven growth europe us tecentriq first approved chf billion approved either alone combination alecensa first approved chf million targeted therapies andor chemotherapies various treat alkpositive lung cancer alecensa forms nonsmall cell nsclc small cell lung showed continued strong sales growth across cancer certain types metastatic urothelial cancer regions europe international region pdlpositive metastatic triplenegative main driversbusiness performance roche incremental sales chf millions ocrevus neuroscience hemlibra haemophilia tecentriq oncology perjeta oncology kadcyla oncology running stringent controls medicines ensure products provided patients meet respective requirements avastin oncology gazyvagazyvaro first approved chf million chronic lymphocytic leukaemia cll rituximabrefractory follicular alecensa lymphoma previously untreated advanced oncology follicular lymphoma sales expanded regions polivy first approved chf million part combination therapy treatment actemraroactemra adults relapsed refractory diffuse large immunology bcell lymphoma received least two prior therapies fda granted accelerated approval rozlytrek first approved chf million gazyvagazyvaro lung cancer specific gene mutation oncology solid tumours carrying certain gene fusion rozlytrek received approvals us japan lucentis ophthalmology growth rates report constant exchange rates cer average experience andy telling story scan xtend app watch video new treatment options patients speed roche brings new medicines pdl expression received physicians patients accelerating prior chemotherapy metastatic disease launched two medicines making since initial treatment adults essclc initial preparing launch another two therapy adults metastatic nonsquamous number drug candidates latestage nsclc without egfrmutant alkpositive clinical development increased nsclc combination therapy firstline past three years treatment adults metastatic nonsquamous nsclc people egfrmutant alkpositive ocrevusreducing risk disease progression nsclc tecentriq combination treatment indicated longerterm data phase iii openlabel failure appropriate targeted therapies extension studies opera opera ii oratorio showed patients treated phase iii imbrave study evaluating tecentriq ocrevus continuously six years combination avastin treatment people reduced risk disability progression relapsing ms unresectable hepatocellular carcinoma hcc primary progressive ms results suggest received prior systemic therapy met earlier treatment ocrevus administered coprimary endpoints demonstrating twice yearly reduced risk disability progression statistically significant clinically meaningful effect sustained time improvements overall survival progressionfree survival compared standardofcare sorafenib tecentriqentering new cancer areas study represents first improvement overall tecentriq firstinclass medicine treat extensive survival people unresectable hcc compared stage small cell lung cancer essclc metastatic current standard care triplenegative breast cancer tnbc decade tecentriq approved additional indications across multiple tumour types kadcylaimportant option breast cancer fda approved kadcyla adjuvant us tecentriq combination therapy surgery treatment people herpositive early approved initial treatment essclc breast cancer residual invasive disease fda granted accelerated approval tecentriq neoadjuvant surgery treatment eu plus nabpaclitaxel treatment metastatic kadcyla approved treatment surgery pdlpositive tnbc also approved tecentriq herpositive early breast cancer combination therapy initial treatment metastatic nonsquamous nsclc egfr hemlibrafor age groups alk genomic tumour aberrations hemlibra approved eu routine prophylaxis bleeding episodes people severe eu tecentriq received four additional haemophilia congenital factor viii deficiency approvals patients unresectable locally fviii without factor viii inhibitors hemlibra advanced metastatic tnbc whose tumours used age groupsbusiness performance roche chf million divisional sales erivedge perjeta kadcyla gazyvagazyvaro esbriet cotellic alecensa tecentriq venclextavenclyxto ocrevus hemlibra luxturna xofluza polivy rozlytrek venclextavenclyxto sales booked partner abbvie percentage sales contribution medicines launched since increased steadily gazyvagazyvarobtd lupus nephritis received least two prior therapies continued fda granted breakthrough therapy designation approval indication may contingent upon btd gazyvagazyvaro adults lupus verification description clinical benefit nephritis phase ii clinical study nobility confirmatory trial gazyvagazyvaro met primary key secondary endpoints lupus nephritis severe rozlytrekfor rare forms lung cancer potentially lifethreatening disorder kidneys new medicine approved treatment phase iii programme initiated metastatic nsclc japan ntrk us rosntrk fda granted accelerated gazyvagazyvarocll sll approval rozlytrek treatment adult fda approved venclextavenclyxto paediatric patients years age older combination gazyvagazyvaro treatment solid tumours neurotrophic tyrosine previously untreated chronic lymphocytic receptor kinase ntrk gene fusion without leukaemia cll small lymphocytic lymphoma known acquired resistance mutation sll cotellicbreakthrough therapy designation polivyaccelerated approval fda also granted btd cotellic histiocytic fda granted accelerated approval polivy neoplasms harbour braf v combination bendamustine plus mabthera mutation based phase ii study rituxan treatment adults relapsed adults histiocytosis mutational status refractory diffuse large bcell lymphoma demonstrating high overall response rate nextgeneration medicines continuing drive treatment oncology vision loss major global health problem immunology ophthalmology neuroscience infectious latestage pipeline includes projects neovascular diseases rare diseases strong inhouse agerelated macular degeneration namd diabetic pipeline end new macular oedema dme diabetic retinopathy molecular entities clinical pipeline retinal vein occlusion faricimab first bispecific pharmaceuticals division number antibody designed specifically eye compounds nextgeneration products based phase iii trials dme namd simultaneously successful roche legacy medicines targets two key drivers development time entering disease areas progression diseases pds small refillable scientific progress enables us make meaningful device size grain rice first improvements patients ever continuous delivery system biologic medicine namd currently investigated oncology new medicines follow roches phase iii study strong legacy disease area including gazyva gazyvaro venclextavenclyxto recently approved infectious diseases xofluza firstinclass polivy us polatuzumab vedotin well latestage onedose oral antiviral medicine influenza development compounds including mosunetuzumab xofluza currently approved several countries cdtcb mosunetuzumab cdtcb treatment influenza otherwise healthy two novel bispecific antibodies investigation people october xofluza became first blood cancer relapsedrefractory nonhodgkin antiviral medicine approved fda lymphoma drug candidates demonstrated specifically patients high risk developing compelling early data significantly advanced serious complications influenza expertise developing antibodies treat blood diseases entering new disease areas successful launches ocrevus treatment herpositive cancer perjeta kadcyla two forms multiple sclerosis hemlibra subcutaneous herceptin key medicines forms haemophilia mark roches entry fighting breast cancer follow success disease areas previously focus seen herceptin phase iii federica study similarly latestage development pipeline covers met primary endpoint new investigational compounds several conditions central fixeddose combination perjeta herceptin nervous system including spinal muscular atrophy administered subcutaneous injection combination sma neuromyelitis optica spectrum disorder intravenous chemotherapy demonstrated non nmosd autism huntingtons disease inferior levels perjeta blood pharmacokinetics alzheimers disease compared standard intravenous infusion perjeta plus herceptin chemotherapy people risdiplam potential first oral therapy herpositive early breast cancer method people sma many remain drug administration significantly reduces time untreated data dosefinding part spent receiving treatment pivotal firefish trial show infants type business performance roche roche successfully entering new disease areas providing important new treatments people severe conditions including multiple sclerosis haemophilia development pipeline also covers ailments central nervous system inflammatory bowel disease several rare diseases sma achieved key motor milestones one year population whether given monotherapy treatment investigational molecule combination baseline immunosuppressant pivotal second part sunfish study evaluating therapy fda granted breakthrough therapy risdiplam people aged years type designation satralizumab sma met primary endpoint change baseline motor function measure scale etrolizumab eight large phase iii studies one year treatment risdiplam compared ongoing crohns disease ulcerative colitis placebo fda granted priority review two main forms inflammatory bowel disease risdiplam sma currently cure satralizumab undergoing regulatory review roche comprehensive clinical development many countries nmosd rare debilitating programme investigating dosing safety profile central nervous system disease data potential clinical benefit rg people phase iii sakurastar sakurasky studies suggest huntingtons disease programme includes satralizumab could efficacious treatment pivotal phase iii generation hd study option administered subcutaneously every four rg worlds first largest huntingtin weeks patients across broad nmosd patient lowering studybusiness performance roche someone somewhere going went years ago angela kiraba roche south africa remember crying work happened great britain northern ireland began auditorium budapest hungary february correspond professor j buller empathised listening senior manager roches situation explained condition global medical affairs department three words honest treatment options jumped slideduchenne muscular lack thereof prognosis done dystrophy dmd brothers died post rare genetic disorder age orthopaedic procedures didnt help leg blessing thought roche involved braces aided mobility bit brothers dmd research divine intervention got support could mother back working medical affairs roche south home things getting bleaker africa time thoughts went back peace neighbours understand two older brothers born disease people said cursed started displaying signs progressive muscle avoided us brothers continued deteriorate weakening walking toes age lose weight eldest passed away november three still living native kenya one week buried mother took days brother fathers house second brother died july father neither understanding empathetic distanced us left barely ten years old remember standing mother struggled healthcare system grave taking vow become doctor trying find wrong sons graduated bachelor medicine saw kinds specialists able bachelor surgery worked clinical practice get top neurologist orthopaedic years joining roche surgeon nairobi finally made dmd carry optimism find diagnosis information scarce treatment dmd imagine kind internet days mother hope brothers would research reading newspapers meeting people right reminded every day someone one contacts somewhere going went able reach muscular dystrophy group years ago refer december media release licensing agreement sarepta therapeutics usa sustainable development goalsscience innovation roche science innovation ability capture makes patient unique improved significantly paving way next stage personalised healthcare convert knowledge therapies combined power advanced imaging technology artificial intelligence large databases allows new insights diseases material topics covered chapter patient centricity rd efficiency personalised healthcare realworld data preparedness aging society patient benefit centre data age healthcare rapidly becoming reality stay driven continually improving ability expertise pharmaceuticals diagnostics roche digitally collect aggregate curate make sense forefront effort fulfil promise vast quantities diverse patient data massive truly personalised healthcare phc generation data add value translation processing data deluge new insights patient data inform meaningful data scale help advance research development sophisticated analytics ultimately help provide todays ability glean new insights connecting actionable meaningful information across diverse datasets sizeable number patients continuum carefor researchers physicians digitally reveal differences importantly individual patients would possible otherwise unique characteristics information used develop novel treatments make clinical trials efficient optimise successful field indispensable clinical decisionmaking engage create synergies strong innovative partners leveraging roches deep inhouse linking genomic profiles realworld data expertise diagnostics pharmaceuticals attain deeper knowledge allow company achieve progress throughout two newer developments helping advance entire value chain development field personalised medicine delivery medicine facilitating discoveries first comprehensive genomic profiling lab enhancing clinical trial design reveal yet unknown genetic anomalies accelerating approval targeted therapies mutational patterns driving tumours growth benefit patients second involves power large quantities curated medical data therapy outcome ability mine analyse unprecedented data captured electronic health records quantities data new ways matured point numerous patients next frontier used support development reached integrating two sets data delivery right treatment right namely genomic information realworld patient right time interlinking genomic clinical outcomes information realworld data eg oncology use wearables sensors enable exactly foundation medicine focusing much granular view persons disease course genetic profiling cancer flatiron health including greater ability measure clinical change curating electronic medical records cancer patients eg neuroscience leveraging array decided accomplish jointly starting back powerful partnerships new technologies seize acquired two companies roche opportunities pioneering inhouse strongly supports effort continuouslyscience innovation roche digitalisation healthcare continually improving ability digitally collect curate make sense vast quantities diverse patient data translation data ultimately help provide actionable meaningful information researchers physicians importantly individual patients updated deidentified data includes patient outcomes clinical outcomes study revealed strong data flatirons network oncology clinics linked link tumour mutational burden tmb comprehensive genomic profiling insights response cancer immunotherapy foundation medicines database rapidly growing example patients high tmb lived almost clinicogenomic database cgdb already contains twice long low intermediate linked profiles spanning many tmb treated antipdpdl tumour types expected become key asset immunotherapies advancing development cancer therapeutics optimising design execution clinical one current use cgdb involves leveraging trials data decide whether biomarker tmb prognostic across wide range tumour types april journal american medical insight may important considering association jama published validation additional development opportunities molecule cgdb acknowledging realworld clinicogenomic also plans use database data data obtained course routine patient source external virtual control arm care yield scientifically clinically meaningful tumouragnostic settings conducting insights corresponding study randomised placebocontrolled trial includes patients nonsmall cell lung cancer nsclc active experimental traditional cgdb investigated effort control arm would difficult see also example understand genomic profiles correlated rozlytrek leveraging realworld data prioritise clinical going forward realworld data increasingly development better design trials determine used building block help develop patient response best molecules underserved patient roche committed developing medicines populations patients highest level unmet medical needs part process understand current examples targeted therapy ophthalmology outcome patients whose disease similar one way oncology look realworld electronic advanced imaging technology new scientific health records patients insights groundbreaking technologies discovery platforms driving development novel highly exactly roche exploring personalised therapies also identification specific target lung cancer includes two conclusive clinical endpoints distinct populations different tumour mutations game changing patients segment looking flatiron health anonymous summarising exciting diagnostic electronic health records tens thousands lung therapeutic innovations taking place field cancer patients standardofcare medication ophthalmology rd roche examine roche discovered patients one tumour new example discovery development mutations worse prognosis higher mortality efforts oncology based data project team decided prioritise development molecules opening new vistas ophthalmology target lung cancer mutation population roches focus ophthalmology development greatest unmet medical need transformational therapies patients major unmet medical need run risk developing potentially blinding retinal disease neovascular agerelated macular degeneration sustainable development goal namd diabetic retinopathy dr diabetic macular oedema dme roche aim create safe effective new medicines diagnostic tests help people rapidly growing aging diabetic live longer healthier lives develop novel populations sheer number individuals medicines therapeutic areas oncology serious eye diseases often result grave visual impairment blindness increasing around immunology infectious diseases ophthalmology world antivegf molecules diseases central nervous system revolutionised treatment many patients pharmaceuticals diagnostics divisions work retinal diseases significant proportion together rd projects sharing research shown partial improvement facilities technologies developments vision diseases benefit benefiting jointly innovations approachscience innovation roche target target b monospecific fab fragment bispecific mab bispecific fab fragment eg lucentis crossmab dutafab eg faricimab new bispecific format dutafabfurther improving standard care bispecific antibodies combine two antigenrecognising elements single construct able bind two targets accounts fact one pathway often root disease phc approach means may able engagement may lead less frequent dosing predict effectively patients respond improved longterm efficacy compared treatment enrolling trials standard care translate leaner efficient clinical trials require fewer patients ultimately support ophthalmology programme bring solutions patients shorter amount roche entered threeyear multiparty time collaboration agreement september establish insight health data research hub addition roche strong pipeline eye health uk insight brings roche investigational molecules ophthalmology together nhshdruk university hospitals early late stages clinical development nongovernmental organisations technology engineered using highly innovative antibody companies establish data hubs across uk technologies accelerate research new medicines therapies technologies support improved diagnosis advanced investigational medicine treatment hub gather anonymised nhs pipeline faricimab firstever bispecific antibody patient data across uk combine enter pivotal clinical trials ophthalmology unparalleled highorder retinal imaging initially dme namd developed using roches focusing diabetes agerelated macular degeneration innovative crossmab technology next generation amd dementia insight provide data bispecific antibodies developed dutafab gathered certain services rapidresponse technology platform entered clinical development realworld evidence ai tools systems users programme intravitreal namd dme testing industry academia fundamental april platform allows generation transformational collaboration reflects roches small extremely stable highly potent bispecific commitment towards establishing strong network antibodies two independent binding sites among many stakeholders playing active role properties increase durability ocular target shaping future healthcare highly personalised cell therapies cancer clear precision goal harness vast area focus roche majority therapeutically relevant patientspecific genentechs first foray field cell therapy neoantigens advance next generation cellular made public january announcement therapies broad range solid tumours collaboration agreement adaptive ultimate vision effectively target patients biotechnologies world leader sequencing tumour cells individual level thereby paving functional profiling tcell receptors develop way development delivery manufacture commercialise tcell therapies truly personalised cell therapy every patient targeting neoantigens long subject pioneering needs research genentech neoantigens proteins surface cancer cells generated tumourspecific neoantigendirected tcell treatments new mutations present patients healthy form cancer immunotherapy fourth cells differ patient patient distinct immunotherapeutic strategy pursued clearly distinguishable normal cellular roche besides immunomodulators proteins neoantigens recognised checkpoint inhibitors tumourtargeted bispecific foreign cells persons immune system antibodies personalised cancer vaccines reason considered tumours example latter genentechs collaboration weak spot achilles heel means german biotech company biontech accessible therapeutic intervention analyses genomic sequence individual patients tumour identify promising cells produced naturally immune neoantigens fight next step insert system also artificially engineered genetic information encoding neoantigens accurately recognise neoantigens adaptive mrnaa messenger molecule biontech biotechnologies responsible developing specifically optimised provide information innovative technologies allow high throughput immune system activate combat analysis beyond proprietary tcell sequencing cancer personalised cancer vaccine could work neoantigenmatching technologies genentech genentech roches checkpoint inhibitors access adaptive biotechnologies extensive provide effective personalised treatment option library billion neoantigentargeting patients combined approach currently tcell receptors tested early clinical trials roche continues explore cell therapy meaningful path adaptive biotechnologies utilise discovery treatment patients platform identify optimal tcell receptors target patients individual neoantigen signature innovating clinical trial design harnessing effectively basis genentech power data design manufacture personalised cellular meaningful data scale realworld setting medicine patient entails reshaping offer tremendous opportunity improve immune system engineering individuals conduct clinical trials making leaner cells cells derived stem cells efficient already realistic scenarios receptors recognise cancers neoantigens electronic health records providescience innovation roche neoantigen infuse engineered isolate directed tcr neoantigendirected collect blood stimulate cells engineering expand cells cells vision design manufacture personalised cellular medicine patient effectively targets tumour cells individual level represent development delivery truly personalised cell therapy every patient needs advantages classic control arm rozlytrek could approved swiftly randomised placebocontrolled clinical trials roche able choose highly innovative way realworld data rwd used designing registrational clinical trials main create external control arm replaces reason roches departure standard way regular standardofcare arm conventional trials running clinical trials comprising control arm possible control arm standardofcare medication active arm rare diseases recruitment takes much experimental medicine fact ros longer due low prevalence disease positivity occurs nsclc patients rare form cancer finding enough patients result enables trial participants enrolled two different trial arms daunting receive experimental medicine speeds challenge addition one main reasons recruitment process lowers trial costs enables nonparticipation clinical cancer trials fear participants treated potentially ending placebo standard ofcare arm effective medicine historical standard therefore roche decided leverage rich expediting medicines path approval rwd electronic health records flatiron screened august fda approved roches collated hundreds thousands cancer rozlytrek people rospositive metastatic patients generating realworld comparator nonsmall cell lung cancer nsclc patients evidence data made possible create ntrk gene fusionpositive solid tumours external control arm eliminating concerning ntrk rozlytrek tumouragnostic need enrol patients real standard control medicine meaning assessed approved arm led increased trial efficiency reducing health authorities based specific genetic driver delays lowering costs speeding lifesaving disease oral smallmolecule medicine therapy market importantly using selective tyrosine kinase inhibitor designed external control ensures patients receive block ros ntrk activity thus promoting active investigational medicine start destruction corresponding cancer cells eliminating concerns treatment assignment data large academic medical centres clinical trial optimisation data community centres patient data cgdb data realworld data guide new treatment genomic profiles deidentified validated development selection foundation medicine plus clinicogenomic scientifically rigorous clinical data flatiron health database demographically diverse electronic health records provide advantages classic control arm randomised placebocontrolled clinical trials realworld data allow creation external control arm conditions require replacement regular standardofcare arm order generate comparative evidence measures change eg mobility big challenge rospositive patients receive rozlytrek roche without welldefined baseline measures started two million patients however evaluating treatment progress clinical flatiron database screened specific trial setting becomes virtually impossible forms lung cancer ros positivity end patients included analysis also case angelman syndrome matched patients rozlytrek neurodevelopmental disorder disease arm study design data interest modifying therapies available rare genetic regulatory bodies allowed us file approval disease affecting approximately one early one health authority without needing individuals devastating disease usually comparative study manifests early childhood around one year age main symptoms severe intellectual remotely measuring quality sleep rare disability lack verbal skills balance movement genetic disease problems seizures sleep impairment neurological conditions difficult find relevant biomarkers identify meaningful carrying earlystage clinical trial endpoints would allow clinicians assess investigational new drug treatment therapeutic efficacy new investigational medicines angelman syndrome roche trying understand confidently number neuromuscular heavily disturbed sleeping patterns angelman neurodevelopmental conditions finding meaningful patients better longitudinally capturing thescience innovation roche syndromes phenotypic features number phase affected young people placing sleeping mats phase ii integrated sensors mattresses subtle fast track phase iii changes movement heartbeat breathing filing rate measured continually data accelerated review sleep quality complemented actigraphic phase duration via device placed wrist information sleep breakthrough therapy years staging rapideye movement rem nonrem etc polysomnography twice year either innovative approaches rd expedited review procedures make hospital home visit nurse new medicines available patients much earlier normal procedure take various readings eye movement heart function purpose tests develop algorithm based rich datasets discerning relevant patterns medical records help answer questions ms patients measures sleep disruption relevant healthcare general highly fragmented lots corresponding changes quantified potentially relevant information patient potential improvements evaluated validated widely scattered multiple formats registries meaningful way light welldefined many different sources hard baseline measures ability measure sleep patients access medical records also relevant many neurological conditions holistic meaningful way therefore understanding sleep taking remote digital measurements help insight led creation neurological conditions well angelman picnichealth digital healthcare company syndrome helps patients collect manage medical records comprehensively blood tests xrays navigating complexity teaming partners patients owners entire medical personalised healthcare become reality history documented records stakeholders healthcare system picnichealth collecting managing electronic work together new ways making sure health records users enjoy full control digital transformation powered data yield health data furthermore compiling records better patient outcomes different disease areas thousands patients structured manner indications order expedite integrated opens enormous opportunities research individualised healthcare solutions roche building important new ways network targeted partnerships collaborations without strong partners complementary skill roches partnership picnichealth launched sets unique technological assets complexity designed exactly namely aggregate challenges need tackled way curate valuable patient data broaden laboratory bench doctors surgery scientific insight centrepiece roches tackled successfully collaboration picnichealth flywheelms observational study combine retrospective result large dataset analysed past seven years prospective five facilitate granular understanding years going forward electronic health records ms patients across us treated disease people living multiple sclerosis ms experienced patients different single database nearly participants therapeutic outcomes first goal enrolled study health records contain understand disease better ultimate aim xrays lab values mri images blood tests also create better treatments tailored individual information comorbidities therapeutic history needs patients multiple sclerosis large datasets curated patient data support deeper understanding patients treated disease experienced patients different therapeutic outcomes aim create better treatments tailored individual needs patientsscience innovation roche working startups bring disease management crc improve screening rate new level currently lower developed countries diagnostics play leading role disease another challenge detect tumours early even prevention management helps face precancerous stage direct patients increasingly complex healthcare challenges appropriate medical followup order better evident vitro diagnostics influence approximately address specific unmet medical need within two thirds clinical decisionmaking despite crc roche piloting machine learningbased accounting total healthcare clinical algorithm medilab salzburg austria spending algorithms developed medial earlysign israel risk assessment tools identify high evolving digital technologies advent risk individuals crc based standard digital health roche saw opportunity laboratory test parameters complete blood count expand diagnostics portfolio include new digital plus patient age gender addresses non solutions thus complementing sometimes compliant population screening patients challenging traditional innovation approach still asymptomatic acts safety net roche decided seek new ways cooperating people positive result followed startups bring complementary strengths evaluation based clinical judgement table outofthebox thinking care provider pilot completed provide breakthrough technologies novel digital tools roche first experience application machine learningbased clinical algorithms therefore roche took decision initiate private lab environment sponsor startup creasphere launched since developed largest hub diabetes creating open ecosystem digital health innovation europe end valuebased care almost startups participated one diabetes chronic disease one highest week creasphere accelerator programmes prevalence rates worldwide around million referred batches working pilot projects people affected displaying staggering growth together roche aim develop digital rates many countries especially africa south health solutions challenge optimise clinical east asia middle east latin america practices improve data analytics help patients individual journeys roche active field pioneer innovative diabetes technologies clinical artificial intelligence identify people years brand accuchek high risk crc world leader blood glucose monitoring colorectal cancer crc second leading cause glucose meters test strips lancing devices offers cancer death deaths established portfolio insulin delivery systems worldwide whilst treatment options insulin pumps infusion sets improved last decades screening tools diagnosis treatment diabetes made great stagnated colonoscopy gold strides recent years many people diabetes standard one key diagnostic challenges still failing reach therapeutic goals structured structured assessmenttraining therapyadapted smbg integrated personalised treatment effectiveness structured diabetes assessment documentation management ipdm personalised systematic analysis treatment significant improvements hbac higher patient physician satisfaction rates increased patient adherence compared control groups result integrated personalised diabetes management approaches smbg selfmonitoring blood glucose diabetes highly complex condition extended early include numerous countries difficult control manage many people integration cgm data mysugr developing serious diabetesrelated health roches worldleading mobile diabetes management complications much earlier would case application since may important step individually tailored optimal disease management approach therefore strategy create leading open ecosystem personalised diabetes management view complexity integrated personalised solutions embedded fully connected diabetes management ipdm necessary data analytics platform view offering order shape advance way diabetes care outcomebased easytohandle care solutions provided future roche creating leading support healthcare professionals bring true open ecosystem ipdm already made relief people diabetes significant progress broad range partners experts solution providers contributing importance intellectual property innovation roches open ecosystem aim broadening roche invested almost fifth accelerating access better diabetes care annual sales rd follows investments around globe key words context similar ratio previous years provide new connection integration integrating relevant therapies diagnostic tests services people data connecting devices also technologies need investments also basis analytics one system longterm commercial success one recent example roches commitment order allow continued investment driving ipdm distribution longterm patents intellectual property rights insertable eversense continuous glucose monitoring provide timelimited exclusivity innovations cgm system senseonics partnership disclosure inventions patents fosters two companies announced late development new improved therapiesscience innovation roche pharmaceuticals clinical pipeline fda breakthrough therapy designations granted since phase phase li phase ill registration oncology inflammation immunology neuroscience infectious diseases ophthalmology spark therapeutics others pipeline new molecular entities covers broad range diseases highly innovative technologies applied create produce active moleculesscience innovation roche child wheelchair ill victoria school student switzerland nine years old go school village annoying sometimes think would nice switzerland school personal assistant could walk child wheelchair helps everything ill changing shoes taking coat gloves giving books helping write get bothers always dependent tired live spinal muscular atrophy sma help means always wait wheelchair support addition personal assistant school helpers come enjoy school lot favourite subjects twice month help showering german maths music classmates go brushing teeth still child sports go physiotherapy sessions help deal different people around good friends school one also grow get help wheelchair sma years parents sister grandparents older lot fun together younger sister sophia four years old earlier year operation scoliosis started kindergarten year two titanium rods back top sma like see running appointments weekly basis jealous form great team home also go doctor every three months usually give instructions helps grow millimetres extends rods want also maja cat home magnet little bit time afraid first shy spent lot time taming soon learnt hurt comes close hands pet children sma like never running live sma results around like kids hope enough strength walk things able move arms around dont think get weaker grow older really cure scientists could try produce afraid future strange feeling medicine stabilises us like parents explained sma know still move little already improvement live every day need companies make medicines help children play something reach adults live good joyful life experience victoria telling story scan images xtend app watch video sustainable development goalsaccess healthcare roche access healthcare innovations meaningless reach need want ensure sustainable access picture stems photo competition faces hope initiated roche pakistan amateur professional photographers captured emotions people recovering disease care material topics covered chapter sustainable healthcare systems availability healthcare affordability healthcare partnershipsthe basis success order tackle complex access challenges successfully collaboration multiple stakeholders essential roche patients heart everything improve access drugs products acutely aware matter dow jones sustainability indices recognition innovative effective medicine may efforts field meaningless need unable access committed facilitating rapid addressing affordability interest patients broad sustainable access innovations multiple programmes approaches global scale working ensure successful treatment restricted finances order tackle complex challenge successfully essential collaborate range roche works close partnership governments stakeholders focus root causes access healthcare systems decisionmakers barriers roche teams working improving access adjust costs help make sure medicines close collaboration healthcare systems affordable sustainable basis government agencies patient advocacy groups organisations adjustments based multiple criteria including countrys gdp gross domestic product although affordability barrier accessing ppp purchasing power parity per capita treatment look root causes behind public healthcare expenditure calculation lack access care often see also considers countrys position human number different factors consider instance development index created united awareness symptoms screening diagnostic nations development programme emphasise treatment capacity core barriers exist people capabilities ultimate various forms degrees one location criteria assessing development country next economic growth alone throughout roche continued make patient support programmes progress several ongoing access initiatives access cancer medicines pakistanthe unmol embraced many new programmes concentrated programme facilitating access patients need named urdu word precious unmol moreover proud acknowledged programme offers sustainable financial solution industry leader category strategy cancer patients pakistan averageaccess healthcare roche new diagnostic tests nextgeneration medicines represent options unmet needs potential increase number patients requiring support accessing therapies income per capita low usd per year access medicines irrespective ability healthcare makes gdp pay last years genentech helped patients must pay treatment two million patients access medicines pocket genentech patient foundation provides roches wellknown cancer medicines medicines free people meet certain included programme pakistan federal financial criteria insurance whose government covers cost treatment insurance cover genentech medicine neediest patients roche pakistan providing afford medicine every year remainder treatment free charge foundation provides muchneeded medication end programme benefited patients free charge approximately patients add innovations portfolio number genentech patient foundation patients need help accessing medicines usbased genentech member roche group likely increase plan expand committed ensuring americans programmes accordingly united nations development programme httphdrundporgencontenthumandevelopmentindexhdi roche supports global access program since aim significantly increasing availability hiv testing supporting efforts fight aids successful programme extended tackle additional infectious diseases structured donation programmes developing countries roches participation committed working partners across wfh humanitarian aid program consists healthcare sector find solutions donation hemlibra funding support sustainable one example efforts wfh programs integrated care development training address gaps care provide consistent donation substantially increase access predictable access treatment people providing prophylactic treatment many haemophilia people haemophilia five years countries little treatment roche joined european haemophilia available consortium ehc partners programme focuses sustainably improving access quality improving access diagnostic tests care haemophilia b ehc partner limited access diagnostic resources leads countries europe central asia spread preventable diseases loss life developing countries lack screening early detection moreover february roche joined world resources prevent transmission leading federation hemophilias wfh humanitarian causes deaths infectious diseases aid program landmark initiative leading efforts remedy lack access care treatment global access program established people hereditary bleeding disorders increase access diagnostic testing line withaccess healthcare roche unaids goal aim procedure prior cit framework approximately people living hiv know patients access immunotherapy disease status diagnosed new framework estimated patients hiv infection receive sustained antiretroviral access threeyear period therapy receiving antiretroviral therapy viral suppression roche works payers devise financial arrangements rooted actual outcomes working collaboration global partners medicines deliverthe differences make programme highly successful providing daytoday lives patients access testing training healthcare workers boosting capacity healthcare system combine results clinical trials realworld evidence includes quality life roche expanded programme include socioeconomic impact much tests tuberculosis hepatitis b c human combined information helps payers allocate resources papillomavirus hpv leading cause cervical according actual overall benefit treatment cancer involved collaborating clinton provides rather spending money health access initiative foundation hope impact innovative new diagnostics others linking payment agreements outcomes expansion global access program aimed better ensure scarce healthcare resources helping meet disease elimination directed treatments effective targets hepatitis cervical cancer tuberculosis example roche supported three local increasing outcome certainty healthcare studies generate data avastin firstline treatment systems lung cancer china avastin received technical clearly understand clinical financial approval chinese national medical products outcomes treatment equip healthcare administration providing chinese systems way facilitate fully informed patients access decisions effective ways allocate resources process developing outcomebased agreements payers results flexible pricing systems times one successful example cancer immunotherapy cit framework belgium roche working many patients access cancer belgian minister health partners help patients access effective immunotherapy immunotherapy belgium thanks treatments almost one year earlier would collaborative efforts otherwise possible standard reimbursement meeting patient needs low middleincome countries patients low middleincome countries face initiative issued access accelerated range barriers receiving vital medical care action key learnings program design timely manner including implementation report outlining principles disease awarenessdoes patient know good programme design highlighting examples contracted illness successful implementation roche timely diagnosishas diagnosis made launched partnership boston university early enough treatment effective develop projects build upon metrics funding challengesare resources available framework provided report projects enable patient receive treatment reported boston university access observatory publicly available database covering world health organization world publicprivate industry partnerships aim bank estimate half global population improve access preventive treatment services estimated billion peopledo access low middleincome countries essential health services additionally access medicine foundation estimates two billion city cancer challenge ccan people access essential medicines multisector initiative supports cities partner organisations roche design planning implementation cancer committed addressing access challenges treatment solutions reduce premature deaths range programmes ncds access accelerated initiative specifically project advancing citybased noncommunicable diseases ncds fastest oncology asuncin paraguay cali colombia growing diseases low middleincome kumasi ghana yangon myanmar cities countries cause extensive economic social serve combined population million hardships initial efforts already effective cali collaboration among healthcare example ccan needs assessment led pharmaceutical companies europe japan allocation usd million diagnostic north america works towards future equipment asuncin resulted anyone living ncd access highquality adoption national cancer law treatment care mission aligned united nations sustainable development goals roche leading industry partner plans focus ncds universal health expand ccan initiative include cities coverage view developing launchingaccess healthcare roche low middleincome countries global access program supports efforts fight infectious diseases lowincome countries lower middleincome countries upper middleincome countries ccan model upscaled globally kigali perspective part needs assessment rwanda porto alegre brazil tbilisi georgia process focus group discussions patient became first cities take part next phase focused events gather information patients len mexico greater petaling malaysia experience cancer care services recently joined ccan programme city specifically greatest barriers challenges accessing quality late ccan serves million people cancer care services engaged healthcare professionals mobilised local organisations currently involving needs assessments generating data patients needs assessment process used develop evidencebased cancer policies current cities january data points assessments collected stored city ccan works civil society providing capacity realtime analysis patient organisations ensure patient voice reportingaccess healthcare roche improve supply chain resulting cost markups putting modern cancer therapies reach ladi hameed roche nigeria best medicine little worth patients transferred patients paying reach time imagine pockets one stage paying pay every cent healthcare costs difference usd every month make less dollar day reality wellknown breast cancer blood cancer many nigeria one primary reasons medicines broken suboptimal supply chain sometimes led cost markups one major changes made involved leading physicians even told us business model roche products nigeria went reluctant prescribe medicines pure marketing services company reach patients buyandsell operation meaning could bring medicines took risk one first roche affiliates sub forex fluctuations upon importantly saharan africa take action one main could supply crucial medicines hospital problems faced multiple distribution pharmacies directly without constantly affecting levels nigeria would go main distributor prices step removed several layers subdistributor several subdistributors markups brought almost reduction finally getting end user hospital price medicines immediately improve supply chain driving costs putting modern cancer therapies achieved roche nigeria reach empowered approach state federal governments open discussions reimbursement first individual throughout complex make sure patients receiving distribution chain would add markups therapies doctors thought best cost medicines secondly start state governments agreed cover concern quality products treatment costs breast cancer patients often cold chain weak link third major discussed federal government create problem drugs imported directly fund critical illnesses number patients us distributor behalf kept could access roches modern medicines rose pushing costs meant control almost currency fluctuation would immediately doubling sustainable development goalsour people roche people working together supports collectively sustainably create make impact society building basel switzerland provides layout cafstyle tables informal meetings material topics covered chapter talent attraction retention organisational agility patient centricity working together help patients working roche gives us opportunity enhance early diagnosis diseases improve health patients clear meaningful purpose people healthy workplace feel company come work day passion energy genuine interest wellbeing creativity focused making truly differentiated contributions working together means sharing common values also means seeking valuing roche culture serves common foundation others diversity working together achieve defines us company embodies even greater impact survey employees values people expect workplace said treated respect dignity courage integrity passionand sets high testament part roche standards expectations people culture yearsa deep focus around globe commitment people employee engagement feedback provide strong preparing people organisation future indicators company culture lived employees believe roche great culture reality roche conducted periodic global employee take purpose heartdoing opinion surveys geos since patients need next foundation vital introduced new engagement tool partnership think prepare leverage opportunities confront glint roche employees participated challenges even greater confidence creativity results refer employees focus took survey asked employees fundamental question happy working roche new people practices introduced employees responded happy two years ago embedded across moreover employees believe work organisation important element solid accomplish roche positive impact society foundation focus agile goalsetting frequent meaningful conversations numbers impressively high coupled employees managers enabled roche high degree confidence roches future adapt nimbly fastpaced changes prospects serve sound basis ongoing work rapidly arising opportunities including digitalisation transformation render processes simpler enhanced capabilities enable us bring focused addition people working groundbreaking diagnostics medicines roche share opinion company offers patients fasterour people roche finding innovative solutions medical needs heart ideas research help save lives kinesis shift mindsets leaders general managers functional heads scientific ensuring new approach leadership technical leaders participated since best important part roches second part encourages leaders apply readiness future ensuring remain insights first part profoundly highly attractive employer end introduced area company supported internal kinesis nearly three years ago leadership selforganised agility working group development programme designed shift mindsets employees nominated senior leaders introduce tangible approaches help taken part least one programmes transform roche agile organisation kinesis senior leaders participated next consists two parts first part programme level kinesis called synergy focuses designed offer leaders deep insights sustaining roches transformation operating behavioural patterns senior leaders including highly networked dynamic setting impacting healthcare leadership development success number cervical cancer njia kiswahili path leadership development screenings increasing threefold compared programme yet another way regions positive feedback participants preparing leaders agile ways working partners programme introduced increasingly unpredictable environment india programme run collaboration ngos governmental institutions tanzania change new environment require us learn launched goal tackling every day employees must access learning cervical cancer burden countrys kagera region tools offer right content right format leadership development thanks njias right time introduction cornerstone studies show nowadays spend less working day deskour people roche fiveyear corporate goals women key leadership roles key leaders diverse work experience employee engagement rate top quartile numbers brackets refer top quartile benchmark fiveyear goal baseline fiveyear corporate goals global learning system september paved way new approach learning fiveyear corporate goals include three goals starting essential training long term indicators great place work system offers modern learning techniques makes easy people know kind training roche conducted periodic global employee opinion surveys relevant certain time evolving learning geos since period set goal strategy also supported piloting linkedin top quartile benchmark companies terms employee learning humu roche platforms engagement fiveyear period employee provide thousands online learning resources engagement measured using methodology aon hewitt employees results pilot projects final year also glint change glint help us explore scaling potential across gain deeper insights extensive comments possible organisation survey question frequent targeted pulse checks please see key results glint survey personalised professional journeys one element efforts adopt new mindset diversity inclusion also part overall corporate goals adapt changing employee needs focused two dimensions firstly goal increase number career development company operates women key leadership positions secondly increased agility flatter hierarchies also increase number key position incumbents experience requires new approaches career development developing established regions achieved new personalised career philosophy fiveyear goal gender diversity year early introduced across roche focusing key position incumbents diverse experience made good individual requires lead fulfilled professional progress first three years although fell short meeting life working towards common purpose overall target improving healthcare entails vary depending particular phase persons life career well unique interests capabilities one approach might include gaining experience another department location roche via specific projects particular development programme matter individual decides move forward career journeys roche require healthy dose curiosity selfawareness hunger keep learning every single day working new ways advance healthcare points approval committees previously used employees true selves work feel early development team decided approach part empowered team shared purpose decisions needed basis involving experts use collective capabilities expertise clearly required increased sense creativity find meaningful solutions roche ownership accountability working well positioned achieve mission bringing different projects well quality speed new medicines diagnostics patients faster decisionmaking one example benefit better heart agility roche agile approach seen case tecentriq triplenegative breast cancer reimagined transformation project undertaken team filed fda approval less weeks pharma product development organisation instead usual case point goal bring medicines patients faster accelerating development similarly life cycle teams comprise variety without compromising quality experts decide upon future development product began work differently attendance simplifying processes considered key based need frees time people acceleration therefore instead static decision required specific topic discussion makes entire process efficient easier people often work different countries time zones sustainable development goal new way working requires experts united nations sustainable development holistic view addition deep expertise goal ensure healthy lives promote open learned wellbeing ages also important past failures willing share workplace roche supporting experiences others enables broader goal number initiatives live community learn quickly build past achievements rather reinventing wheel well campaign example held every time also empowers team potentially september translated theme healthy halt projects devote attention priority relationships local activities fit initiatives needs roches employees cultural setting across different sites project ensuring roche great place work included programmes devoted healthy successful company strives place nutrition psychological counselling courses talented people want work must offer inclusive resilience aim campaign raise healthy work environment good working awareness diverse live well events conditions effective methods dealing take place throughout year site change transformationour people roche supporting gender parity one way working create diverse inclusive culture resilience ability maintain balanced one concrete effort continuously raise awareness attitude towards work new technologies key around diversity inclusion international essential element healthy sense balance womens day celebrated worldwide march feeling respected individuality thirty womens networks exist roche engaged diversity ability bring ones authentic self dialogue colleaguesirrespective gender work every day sense strengthened topic equality diversity inclusion coupled feeling belonging team works towards common purpose second global diversity inclusion week additional milestone roches commitment took part commitment place work place october event included sessions drive innovation roche dedicated supporting covering mental health inclusive leadership diversity inclusion works accordance global sessions conducted virtually un sustainable development goal achieve gender allowing roche employees participate matter equality empower women girls roche located week brought together promoted equal opportunities measured employees across roche objective emphasise many women reach leadership positions key step importance diversity inclusion towards equality future success sustainable development goalsenvironment roche environment roche seeks sustainable technologies minimise impact environment acting photovoltaic array new car park building site kaiseraugst switzerland material topics covered chapter energy efficiency longterm mindset minimising impact ecosystem take responsibility appropriate measures address pressing environmental issues commitment environment environmental specialists inspect facilities reducing amount waste using less environmental performance implementation energy also developing processes environmental policy compliance make business sustainable roches legal requirements internal standards process mitigating environmental risk committed monitoring performance multidisciplinary focuses prevention continuously aim cover least system proactive reduces costs key performance indicator increases efficiency enhances competitiveness ensure compliance high standards group safety security health environmental objectives guarantee processes protection departments audit team well equipment state art noise pollution emissions water energy consumption roche ecobalance emissions air water consumption landfilled wasteenvironment roche solar power programmes genentech member roche group make organisation largest corporate generator solar energy san francisco bay area developed clear defined process striving reduce many ways minimise environmental impact setting metric provides us global view initiating action plans affecting earths ecosystems gives roche focused reducing environmental local site management freedom develop impact measure total environmental impact appropriate strategies objectives curb using ecobalance metric system environmental impact groups ecobalance points allocated ecologically relevant parameters goal achieved product stewardship consumption energy resources sustainable construction two longterm initiatives emission byproducts waste significantly contributed ecobalance business activities ecobalance considers many reduced environmental impact environmental parameters impact developed swiss federal office environment compliant latest guidelines product stewardship main contribution society deliver psp tool starting new tool enable innovative diagnostic tests medicines development teams score improve product save improve lives also design performance stage product take responsibility along stakeholders life cycle respect important business minimise impact medicines sustainability product stewardship objectives diagnostic products safety security health taken together ecobalance product environment throughout entire product life stewardship scores paint complete picture cycle essence product stewardship roches global sustainability impact actively supports sustainability programmes operations products highlights areas important part roches rd activities opportunities improve drug manufacturing use environmentally friendly chemicals materials innovative innovative product design technologies help minimise roches ecological diabetes care design process engineers footprint redesigned blood glucose monitoring strips meters packaging completely improve material outcome product stewardship improves roches efficiency reduce waste new innovative strip ecobalance development production architecture resulted strip size smaller distribution use phases product prior version fewer components benefits address broader range overall new design reduced polyester usage impacts complement ecobalance score roche approximately tonnes per annum moreover developed product stewardship performance new packaging bundles configurations improved pack density allowing products shipped skids tertiary containers reduces distribution cost sustainable development goals environmental impact optimisations achieved reducing thickness weight roches ecompetition gives employees cardboard paper product information opportunity submit ideas environmental increasing use recycled corrugated distribution protection activities suggestions improving components utilising packaging materials certain manufacturing processes certified forest stewardship council resulted major cost savings innovative packaging design ideas including measures reduce energy cancer drugs herceptin avastin consumption airconditioning systems come elaborate packaging protect product proved useful multiple sites eighth accommodate product information typically edition competition reducing one vial one insert per package clinics energy consumption got interest accumulate large numbers vials need well improving logistics respect stored coolers vast quantities packaging packaging transportation concepts waste needs disposed starting withenvironment roche development end life reuse recycle production product stewardship cycle use distribution product stewardship business process used management products throughout entire life cycle ensure products developed produced used disposed responsible manner end user mind genentech engineers researchers donate excess supplies time developed new generation packaging known either directly repurposed within genpack comes two sizes centralised supply system given local schools accommodate ten vials single insert genentechs partnership biolink one package benefits clinics include lower labour equipment depot nonprofit organisation dedicated costs put away product less packaging waste boosting scientific education donated supplies manage less consumption packaging materials equipment since programme started inserts genentech genpack evolved actively diverted significant amounts laboratory winning idea submitted internal sustainability supply waste landfill positively impacted innovation competition local schools students less waste rd environmentally friendly medicines scientific research constantly evolving mabtherarituxan avastin herceptin lucentis projects change end supplies equipment monoclonal antibodies generated large languish shelves cabinets storage proportion roches group sales belong space runs items usually end waste defined class active pharmaceutical ingredients stream affects ecobalance help reduce apis exempt european medicines agency waste minimise companys ecological ema guideline environmental risk assessment footprint genentech hosts annual lab supply products low excretion rate sidewalk sale excess supplies equipment judged present significant risk sewage works collected laboratories across south san surface waters termed benign francisco campus oneday event nature constitute environmentally sustainable researchers pick supplies actually compounds nevertheless chemical need leftover supplies donated local products subjected rigorous environmental schools programme evolved years risk assessment sustainable construction roche committed creating better workplace relevant requirements buildings entire benefits employee environment performance evaluated planning sustainable construction comprises structures stage end life cycle since construction processes occupancy processes guidelines group directives addressing energy consider economic environmental sociocultural conservation place enforce systematic aspects throughout buildings life cycle employee approach towards improving energy performance productivity shown increase buildings sites include energy efficiency standards offering daylight better views better indoor design new equipment buildings air moreover job seekers increasingly paying optimisation existing energyconsuming items attention new potential employers stance sustainability issues critical components minimising energy use sustainable construction reduced energy reduce operating energy consumption water consumption using renewable energy buildings designed way improve reflected roches ecobalance since turn energy performance also includes high millennium roche optimising performance windows extra insulation walls constructions energyefficient aim ceilings doors addition effective window reducing greenhouse gas ghg emissions placement provide natural light reduce zero middle century need electric lighting minimise energy losses via glass particular highly efficient ventilation roche standardised sustainable construction air conditioning instrumental buildings accordance requirements drawn energy performance approach applied new clear regulations implemented throughout roche facilities across global organisation newest specially developed software tool makes possible office building south san francisco production carry construction projects compliance building mannheim designed provide optimal working conditions operate less energy standard result buildings awarded leed gold certification sustainable development goal platinum certificate respectively german society sustainable building headquarters basel waste water treated dedicated facility however led lights lights choice antibiotics buffer biotech efficient highefficiency fluorescent lamps removed way guarantee fitted roches buildings reduces operating expenses waste results feed directly compliance overall discharge permits ecobalance thereby minimising river rhine cases new approach ecological footprint another example minimising introduced sends waste water energy use innovative faade building nanofiltration unit thus concentrating basel triple thermal panes combined closed waste water removing cavity air integrated sunscreens reduce glare critical components comply permits help insulate interior heat coldenvironment roche since total projects completed avoiding tonnes co emissions led estimated costsaving approximately chf million sustainable energy sources energy efficiency building basel heated energy recovered sensors workstation detect someone manufacturing processes ground water present turn lights ventilation remains constant temperature degrees automatically monitoring system celsius used cool building summer whole building track energy usage approximately roche sites around world source energy efficiency might one bestknown electricity either factors sustainable construction energy providers generate electricity one issues also critical water solar wind power circular economyin words production solar panels installed site solar panel system consumption model existing materials meets percentage sites total electricity products shared leased reused repaired requirements rest comes energy providers refurbished recycled long possible example solar panel system suzhou recent buildings basel site china produces enough electricity sunlight rubble broken site mixed form cover almost administrative buildings fresh concrete around concrete energy needs equivalent power almost used recycled reduces amount transport private households entire year three needed dispose concrete waste deliver roches sites california successfully installed new materials conserves natural resources solar arrays within last years ie gravel direct positive impact mid generated approximately roches ecological footprint gj electricity supplying sites electrical needs cases electricity sourced generated without emitting ghg positive impact roches ecobalance environmental performance data roche measures environmental impact using environmental impact per employee taking business ecobalance metric key metrics method growth account strategic goal reduce ecofactors measure environmental ecobalance impact pollutant emissions resource extraction reached target since activities ecopoints per unit quantity aiming reduce footprint points added related total number year see ecobalance performance employees enables us monitor fiveyear goals share sustainable energy ecobalance million pointsemployee energy consumption gj ffeemployee general waste kgemployee water consumption memployee goal ffe fossil fuel equivalent weighted water stress changes related respectivelyenvironment roche co equivalent emissions tonnes ecobalance scope fuel combustion halogenated hydrocarbons emissions scope air scope business flights scope direct emissions generated within facilities scope indirect emissions purchased energy scope indirect emissions included scope value chain marketbased data emissions air tonnes vocs particulates nitrogen oxides sulphur dioxide volatile organic compounds halogenated hydrocarbons tonnes inventory consumed released global inventory including chugai genentech ventana energy consumption terajoules energy total scope scope consumption energy scope scope consumption gjemployee data collected group gj gigajoule water usage discharge water withdrawn million water consumption water consumed million emissions organic matter discharged waterways treatment water heavy metals discharged waterways treatment kg landfilled incinerated waste tonnes general waste generated landfilled chemical waste generated waste contaminated soil construction waste sustainable development goalscommunity engagement roche community engagement works best built meaningful relationships mutual trust philosophy following century deliver sustainable outcomes working side side aftermath heavy earthquakes floods nepal roche partners ngos habitat humanity help rebuild communities material topics covered chapter longterm mindset availability healthcare strong partnerships strong communities order make lasting impact roche liaises local partners assess needs take possible action whether longterm commitment provide comprehensive services communities urgently needed response seek achieve lasting little access essential healthcare improvements society main focus areas services today coach trains involve humanitarian social efforts community six clinics board equipped environmental projects science education pharmacies diagnostic tools diabetes programmes arts contemporary culture cancer screenings breast examinations cervical prostate cancer checks trains roche long history philanthropic engagement provided free primary healthcare services began supporting international people across rural communities committee red cross hundred years ago evolved impressive string grown remote area south lasting partnerships accredited nongovernmental africa thabisile knows impact phelophepa organisations ngos world wide fund beyond healthcare benefits nature wwf unicef habitat humanity trains also boost local economy become trusted partners critical areas high unemployment rates able offer work trains communities staying track many years come stop top permanent staff selectively developing supporting live work trains nine months year implementing innovative solutions together train also provides platform experiential local partners aim simple measures learning students various disciplines bring lasting improvements make studying south africa beyond sustainable impact society two south african phelophepa primary healthcare trains leading one longestrunning publicprivate example roche transnet countrys partnerships south africa phelophepa speaks main freight logistics company came together volumes roches unwavering commitment provide free primary healthcare rural areas country train accompanied nation marking th anniversary collaboration journey incredible change potentially roche renewed support initiatives main era bring universal healthcare external sponsor efforts roche seen respected partner transnet also people south africa years mobile health clinic come long way recalls thabisile makhaye phelophepa delivering urgently needed help operations manager humble beginnings sustainable way threecoach train stateoftheart primary due climate change increasing healthcare facility two trains able demand respond weather disasters primarilycommunity engagement roche support programmes benefit active longterm commitment initial emergency phase partner local authorities relief organisations support sustainable rebuilding efforts roche also sponsors development training centres help communities prepare future threats cyclone idai hit mozambique zimbabwe malawi one worst tropical storms affect africa response able help via three ngo partners donated mosquito nets vital muchneeded piece equipment prevent transmission malaria country longterm partner unicef journey continues thabisile makhaye phelophepa operations manager front conjunction wwf supporting roche health clinic coach celebrating years successful partnership roche construction two community disaster relief centres zimbabwe also provided funding ngo actionaid roger federer foundation help rebuild preschools malawi see box addition roche portugal granted funding portuguese branch red cross support people affected sustainable development goals disaster mozambique also donated units bactrim roche antibiotic part emergency disaster relief efforts since roche employee action charity trust react partnering recent efforts build upon ongoing disaster roger federer foundation rff support relief commitments across africa asia local ngo actionaid build four model preschools example following heavy rain flooding satellite preschools malawi march affected kenya partnered wwf help country devastated cyclone idai fund construction two disaster relief centres preschools roche supported along lower reaches tana river following affected provided additional funding severe floods nepal collaborated rebuild preschools damaged habitat humanity build homes safer areas rapid unbureaucratic aid roche restore damaged housing houses extremely valuable allowed us resume completed another almost ready service quickly possible children addition households benefited disaster resilience training locals attended miss education commented janine specialist masonry courses hndel ceo rff believing power education roche dedicated programmes promote son family first household educational opportunities young people around obtain university degree opportunity get world equipping academic know education must underestimated essential soft skills initiatives prepare key everything says freshlyminted bachelor students thrive individuals serve business administration roche main communities benefactor able cover expenses studies family would emerging markets one major focal points able bear financial burden eager fund education programmes support talented work marketing business development students poor disadvantaged backgrounds put learned practice engage sustainable local projects ensure students strong employment prospects latin america collaborate fundacin graduation educacin peru colombia el salvador guatemala launched roche provides focus disadvantaged youngsters fouryear scholarships talented young people india funded college university scholar lowincome families leading colleges ships students kiran childrens village universities much like indian south african disabilities literally meaning scholars students also great likelihood ray light kiran provides rehabilitation education around finding employment vocational training shines beacon light respective countries lives disadvantaged youngsters attending university varanasi rochesponsored asked one foundations recipe students become first generation success president fundacin educacin village go higher education ricardo cordero quick answer programme characterised focus concentrate finding students received scholarships best talents four countries active roche graduated maharishi institute ten schools moreover focus attention johannesburg another students set needed economies countries graduate institute nonprofit question solely sponsor economics business organisation aim educating new administration students thanks highly generation leaders south africa providing motivated dedicated team able offer truly funding students looking access education tailormade highly sustainable programmes offered educational partners future employment prospects graduates giving back community maharishi proved highly successful leaves also sets scholarships apart lasting impact students also programmes compromiso de honor principle families communities scholars finished studies expected repay scholarship provided one years graduates nkulumo dlamini financial means real contract soweto township johannesburg youngest simple oath graduates happy socommunity engagement roche bright future ahead first batch rochesponsored students maharishi institute johannesburg graduated foundation also fosters active alumni career started enterprise seeing scholars network says ricardo way succeed aim continuously grow programme promote networking among scholars alumni thanks roche strategic partners also actively stay contact gradually want know happens four years scholarship see worthwhile science technology core adjust programme necessary business support international local programmes spark interest roche initially provided scholarships students disciplines among young people europe fundacin educacin first graduated number science education initiatives followed another remainder supporting swiss youth science complete studies ensure years founding sponsor continuity company already committed international swiss talent forum think tank another four years sponsoring scholars roche students world since beginning therefore contributing foundations ongoing istf highly talented young success story president describes thus people different countries participated direct impact scholarships family programme us genentech runs community obvious also rather futurelab cooperation local school district invisible one often former scholars serve role inspire young students explore careers science models younger students made technology engineering mathematics sustainable development goalsintegrity business roche integrity business working integrity professional virtue asked employees matter culture ensure manufacturing processes finished products meet strict regulatory requirements set authorities material topics covered chapter human rights ethics transparency realworld data product quality patient centricity data privacy compliance respect human rights company influences happens employees value chain customers local communities long run successful respect human rights often viewed simply business act integrity trust respect matter compliance however roche takes one everyday operations goes far beyond step aim avoid harm complying mandatory requirements also deliver meaningful positive outcomes making positive impact society stakeholders endeavours subject vital importance operations worldwide human rightsa topic number recent examples roche fostered globally business roche worked partners embed human rights daily business pharmaceuticals stated code conduct support site shanghai china example run respect human rights implemented financing programme small minorityowned un guiding principles business human innovative suppliers need funds rights building protect respect remedy fosters supplier diversity gives us better framework developed harvard professor john access innovation small agile ruggie equally committed un companies global compact principles universal declaration human rights fundamental labour sites basel rotkreuz switzerland rights stipulated international labour penzberg germany collaborate third organizations declaration fundamental parties employ disabled people fully principles rights work integrated daytoday work support us manufacturing supply chain activities also ask affiliates talk human compliance rights achievements provides employees used roche group speakup line available transparency corporate actions languages countries chief compliance officer received reports strengthens relationship stakeholders alleged violations code conduct via business ethics incident reporting system unfounded founded still jointly improving human rights standards investigation result employment contracts agreements business working pharmaceutical partners terminated grounds unethical behaviour supply chain initiative psci revise auditintegrity business roche programme create robust process identification human rights violations implemented risk management programme designed systematically identify assess mitigate adequately manage risk human rights violations programme apply operations also value chain businessrelated activities identified four main human rights risk areas data privacy safety workplace working conditions employee representation published guidelines httpsgorochecomduediligenceprocess provide overview develop implement adequate duediligence process foster inclusion employees disabilities helps identify assess potential impact risks related human rights roche group supplier sustainability assurance visits major findings area working conditions included excessive overtime unsatisfactory compensation overtime insufficient rest days per working week inadequate payment sustainable development goal social benefits conducted supplier sustainability assurance visits resulting findings roches global procurement organisation minor issues lack developed method identifying written safety health policy employees corrective risk human rights violations global action plans implemented suppliers supply base perform site visits make sure suppliers identified roche continued assess mitigate risk risk protect human rights human rights violations using enhanced human discovered human rights rights violation risk process identify risks among labour issues none critical suppliers providers receive reports critical findings among suppliers find evidence child labour suppliers modern slavery see philipp aerni global business local culture springer psci group pharmaceutical companies dedicated establishing promoting responsible corporate practice managing safety quality culture roches philosophy health safety key principle roches strategy keep tabs employees valuable resource roche mental health risks involves three levels prevention committed promoting safe healthy workplace primary secondary tertiary one core element environment employees establish strategy roches health protection directive maintain safe working practices proper separate section dedicated primary prevention procedures direction safety everyones respon mental health problems workplace primary sibility rests levels management prevention designed monitor risk factors employee result safety data shown cause stress may related work marked improvement compared last year work environment social setting see graph however despite efforts employee died company event profoundly regret secondary tertiary prevention organised tragic accident offer sincere according local needs responsibility condolences victims family friends local human resources safety security health environment officers medical services monitoring mental health risks management depending site organised digitalisation globalisation substantial workloads secondary prevention measures aimed job insecurity new hallmarks modern personal capability cope stress example workplace characteristics identified time management courses resilience training help main source workrelated stress potential employees manage individual stress levels mental strain may affect employee health aim tertiary prevention minimise impact existing mental health problems individual counselling employee health safety every roche site must mental health strategy place tackle issue drive forward aid implementation headquarters developed starter pack guidelines also using social media exchange experiences sites furthermore two mental health workshops held roche sites mississauga canada singapore april november respectively attracting participants sites north america apac region main focus workshop prevention mental health problems groups participants given opportunity conduct risk assessment mock goal work situations mental health continue play losttime illness rate roche accident rate important role roche continue offer losttime accident rate number workrelated accidents everimproving healthy working environment working days lost per year due accidents threeyear average employeesintegrity business roche quality engrained culture provision highquality products every patient every time represents foundation approach manufacturing operations quality everyones responsibility believe quality culture formed attitudes actions every single person global manufacturing community believe constant nurturing development quality culture greatest priority seek accelerate delivery medicines patients continued encouraging people look opportunities strengthen quality aspects manufacturing environment focus safeguarding highquality supplies patients example colleague based kaiseraugst site switzerland proposed moving quality assurance team discrete area operate manufacturing line resulting better contributions healthcare patient organisations integration production operations also made simple incremental changes dedicated engaging transparent dialogue healthcare patient increasing numbers visual support organisations grants donations patient organisations totalled boards every shop floor help support chf million healthcare organisations chf million sponsorships people fully understanding new processes healthcare patient organisations totalled chf million details found website rochecomperformance also saw successful conclusion manufacturing quality work plana multiyear journey succeeded addressing car safety technical improvements throughout entire manufacturing network example indianapolis us safety fleet teams joined forces tackle driver safety corrective preventive action system new vehicles must equipped several safety features forward collision introduced disciplined review performance warning emergency braking blindspot detection functions car safety statistics metrics also improved sample management show added safety features reduce number reported car crashes laboratory control system approximately teams also looking bring change behaviour sales representatives whose driving considered risky even dangerous spirit initiative continues via monitored using telemetric solution monitors harsh acceleration cornering braking quality compliance sustainability plan speeding wearing seat belts furthermore drivers required attend seek reinforce changes made eighthour training course entitled behind wheel although programme still drive search opportunities infancy roche indianapolis already recorded drop number car improvement crashes democratising health data datadriven healthcare potential transform regulation gdpr roche building health systems improve outcomes patients considerable data protection expertise gained make healthcare sustainable unlock several decades conducting thousands potential health data needs made accessible clinical trials involving millions patients shared consequently data privacy protection across globe legitimate concern therefore important strike balance protecting personal data instance transparency privacy core using data benefit society balance partnership picnichealth aim transparency foundation datadriven collaboration translate valuable information healthcare system trusted citizens captured patients individual medical records supported different stakeholders data standardised research purposes new approach data sharing patients putting patient centre provided service allows access continue respected preferred aggregated medical records support partner trust us data care consent research programme protection responsible use personal data free common barriers research participation reflected daily operations anchored roche group code conduct endorsed harnessing power data position paper access use realworld collaborating leading companies data rwd roche complies applicable field genomics rwd foundation data privacy laws including swiss data protection medicine flatiron health building act european union general data protection strategic partnerships develop new targeted diagnostics therapies help improve decision making along patient journey one example strategic collaboration sustainable development goal ge healthcare together combining complementary expertise diagnostics develop crosssector collaboration clinical decision support solutions oncology established michael j fox foundation acute care helping healthcare professionals navigate parkinsons research mjff june increasingly complex medical practice make roche providing digital confident decisions timely fashion biomarker platform study funded roche also driving crosssector collaboration mjff crosssector consortium industry academia research aid mobile tool data parkinsons organisations societal benefits disease affects patients life every day collaborations significant people diverse captured aim adopt unified backgrounds come together share ideas high biomarker approach across board quality data work accelerating innovation parkinsons research development area healthcareintegrity business roche roughly citizens willing share health data research security privacy guaranteed advancing regulatory framework rwd also essential clinical development rwd allows regulators make informed rozlytrek one studies feasible decisions safety efficacy value medicines include comparator arm due rarity diagnostics patient groups condition studying developed external control arm using flatiron roche working authorities understand data patients underwent standardofcare best use rwd support approvals vitro treatment comparative realworld data diagnostics new medicines regulate digital successfully used filing japan health products example roche flatiron great example making research efficient health part crossindustry collaboration providing better option participants faster established dukemargolis center health policy us aim collaboration advance policy development related regulatory acceptability rwd united states fdas software precert pilot program roche engages diagnostics tech industry leaders develop novel digital health regulatory framework speeds product access policy maintaining safety effectiveness comes health data topics related innovation access agencies fda ask industry put personalised healthcare engaging public policy stakeholders fundamental forward bestpractice examples rwd aspect good public governance strive strengthen stakeholders utilised regulatory submissions one example understanding ofand trust inour business convinced constructive influenza medicine xofluza fda form lobbying interest parties involved society whole required additional toxicology studies using rwd roche remains independent political affiliation appropriate roche three million tamiflu patients roche discloses contributions signs transparency registers public authorities able show repeated use medicine information found public policy webpage spent pose risk data accepted fda chf million switzerland included payments industry associations additional safety studies conducted various chambers commerce financial assistance trade unions donations consequently rwd saved four crucial years political parties cantonal federal level donations political parties clinical development xofluza became available low doubledigit thousand range swiss francs together accounted us patients much faster approximately total contributions donations european commission results public consultation transformation health care digital single marketintegrity business roche patients want considered partners decision made use data noga leviner picnichealth usa company born experiences patients want considered partners patient diagnosed crohns disease decision made use data everything healthcare system extremely fragmented expectation watching tv shows data fundamentally belongs patient would one doctor charge setting infrastructure processes rely knows everything going reality patients sometimes even aware one really charge care data used research purposes person actually every step every really want system going appointment long run need make sure patient consent also right thing inspired set picnichealth get best outcomes research avoid app developed dedicated compiling electronic creating antagonistic dynamic patients feel health records making available patients tricked fully scientific community authorised understand data used patient app works collecting managing available health records whatever takes patients want research happen also want go get medical records picnichealth better care diseases new treatments organises data personal health record big challenge getting initial hurdle discomfort patients actually us people sensitive personal data big companies using data ecosystem used everybody wants personal data somehow given rise feeling used outside care control turn around need engage overwhelming need patients able contribute patient equal partner bigger picturefor research improve care objection use data realised makes sense generate much data mainly connection nontransparent way real world order understand diseases better done quite often found works one transparent patients got able use transparency issues consent received overwhelming support would travesty material topic covered chapter compliancecorporate governance roche corporate governance strong board directors highly skilled managers act integrity essential wellfunctioning governance roche report sets structures processes rules roche takes basis good governance company principles business activities focus sustainable value corporate governance requirements particular creation innovation management culture applicable laws swiss stock exchange conforming recognised standards good corporate six swiss exchange directives swiss code governance policy transparent communication best practice corporate governance promulgated embody roches corporate governance principles swiss business federation economiesuisse build basis successful implementation companys internal governance framework roches commitment serving stakeholders particularly articles incorporation bylaws embodies principles needed ensure strong board directors represents companys businesses managed supervised interests shareholders manner consistent good corporate governance stakeholders highly skilled managers including necessary checks balances act integrity extremely important printed annual report contains selected links recognised ten consecutive roche website httpswwwrochecom readers years sustainable company thus provided snapshot pharmaceuticals index dow jones sustainability company reporting date also directed indices djsi roche ranked second djsi sources consult time based indepth analysis economic uptodate information corporate governance social environmental performance djsi roche whereas annual report covers single serve benchmark investors integrate financial year ending december website sustainability considerations portfolios contains information permanent nature sustainability core business practices well latest roche news companys articles award reflects commitment running incorporation bylaws curricula vitae business way ethical responsible current former status per end term creates longterm value stakeholders reporting date december year least last five years members board corporate governance report sets directors corporate executive committee structures processes rules roche takes published website basis wellfunctioning corporate governance roche complies relevant details please refer following report httpswwwrochecomaboutgovernancehtmcorporate governance roche annual general meeting annual general meeting board directors board committees board directors chairmans nomination committee board committees remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee ceo ceo ceo general committee cfo hr roche group pharmaceuticals diagnostics counsel enlarged corporate executive enlarged corporate executive committee committee gred pred partnering communications board directors st annual general meeting agm roche organising meeting immediately following holding ltd march shareholders reelected agm board directors determined dr christoph franz chairman board structure composition remaining directors committees shown see also pages board directors corporate furthermore agm reelected andr hoffmann executive committee prof sir john bell julie brown paul bulcke anita hauser prof dr richard p lifton dr andreas oeri peter voser served member board bernard poussot dr severin schwan dr claudia directors roche holding ltd since stepped suessmuth dyckerhoff peter r voser elected member board directors roche prof dr hans clevers additional new member end june due additional role board directors term one year interim ceo abb provided articles incorporation march forthcoming agm addition agm elected dr christoph franz board directors nominates chairman andr hoffmann prof dr richard p lifton bernard exception dr andreas oeri prof sir poussot peter r voser members john bell remaining members board remuneration committee directors reelection july roche announced dr andreas oeri year moreover board directors nominates term office informed board directors dr christoph franz andr hoffmann stand reelection member prof dr richard p lifton bernard poussot board directors agm reelection members remuneration dr jrg duschmal fifthgeneration descendant committee agm founder roche confirmed interest standing election member board due bdo ags resignation july directors therefore board directors independent proxy elected agm proposes dr jrg duschmal new representative view ceasing execution mandates shareholder group pooled voting rights independent proxy pursuant article para election board directors agm ordinance excessive compensation listed jointstock companies vegv board years service board prof sir john directors appointed testaris ag replacement bell also decided stand reelection independent proxy conclusion board directors agm board agm board directors nominates testaris directors proposes addition dr patrick frost ag election independent proxy agm ceo swiss life group election board period conclusion directors agm ordinary agm shareholders board directors board committees board directors chairmans nomination committee board committees remuneration committee audit committee corporate governance sustainability committeecorporate governance roche composition name year birth first elected board directors dr christoph franz c e g chairman andr hoffmann representative c e g vicechairman shareholder group pooled voting rights dr andreas oeri representative e g shareholder group pooled voting rights prof sir john bell e g julie brown b e g paul bulcke b e g prof dr hans clevers b e g anita hauser e g prof dr richard p lifton c e g bernard poussot c e g dr severin schwan f dr claudia suessmuth dyckerhoff b e g secretary dr gottlieb keller board directors honorary chairman dr fritz gerber board directors curricula vitae cvs members board directors current members httpswwwrochecomaboutgovernanceboardofdirectorshtm b former members least last five years httpswwwrochecomaboutgovernanceecbodformerhtm c information cvs reporting date december year least last five years httpswwwrochecomaboutgovernancearchivformercvshtm corporate governance sustainability committee b audit committee c remuneration committee chairmansnomination committee e nonexecutive director f executive director g independent member board directors committee chairperson corporate executive committee william bill anderson former ceo genen tech dr michael heuer assumed ad interim appointed ceo roche pharmaceuticals effective leadership roches diagnostics division january new member corporate became member corporate executive executive committee reporting dr severin committee effective october retired schwan ceo roche group predecessor daniel planned end july oday stepped role ceo roche pharmaceuticals member corporate board directors appointed dr thomas executive committee december prior schinecker former head diagnostics business assuming new responsibilities outside roche area centralised point care solutions ceo provided support ensure smooth transition roche diagnostics member corporate activities end february executive committee effect august dr stephan feldhaus head group communications directors appointed claudia bckstiegel member roches enlarged corporate executive currently head legal diagnostics division committee decided continue career outside position general counsel join company end september barbara enlarged corporate executive committee report schdler former head communications public dr severin schwan april parallel affairs eon se succeeded october dr annette luther currently general manager head group communications member roche diagnostics international ltd rotkreuz roches enlarged corporate executive committee switzerland become secretary board reporting ceo roche group dr severin directors report dr christoph franz schwan information member corporate dr gottlieb keller general counsel member executive committee enlarged corporate corporate executive committee secretary executive committee listed see also pages board directors retire years board directors corporate roche end march board executive committee corporate executive corporate executive committee ceo ceo ceo general committee cfo hr roche group pharmaceuticals diagnostics counsel enlarged corporate executive enlarged corporate executive committee committee gred pred partnering communications composition name year birth position since corporate executive dr severin schwan ceo roche group committee bill anderson ceo roche pharmaceuticals dr thomas schinecker ceo roche diagnostics dr alan hippe chief financial officer cristina wilbur head group human resources dr gottlieb keller general counsel enlarged corporate dr michael varney head genentech research executive committee early development gred dr william pao head roche pharma research early development pred dr james h sabry global head pharma partnering barbara schdler head group communications secretary corporate perolof attinger executive committee statutory auditors kpmg klynveld peat marwick goerdeler sa reporting years roche holding ltd kpmg ag since auditor charge john morris ian starkey mark baillache business year chief compliance officer dr urs jaisli september pascale schmidt october curricula vitae cvs members corporate executive enlarged corporate executive committee current members httpswwwrochecomaboutgovernanceexecutivecommitteehtm b former members least five years back httpswwwrochecomaboutgovernanceecbodformerhtm c information cvs reporting date december year least last five years httpswwwrochecomaboutgovernancearchivformercvshtmcorporate governance roche dr andreas oeri chairman corporate governance sustainability committee andr hoffmann chairman remuneration committee group structure shareholders roches operating businesses organised two integrated roche pharmaceuticals divisions pharmaceuticals diagnostics diagnostics division consists following pharmaceuticals division comprises two business four business areas centralised point care segments roche pharmaceuticals chugai whereas solutions molecular diagnostics tissue diagnostics genentech former third segment diabetes care roche pharmaceuticals incl genentech pharmaceuticals chugai centralised point care solutions molecular diagnostics diagnostics tissue diagnostics composition diabetes care www business activities carried group andr hoffmann vicechairman board six exchange subsidiaries associated companies detailed directors chairman remuneration regulation information roche holding ltd significant committee dr andreas oeri member httpswwwsix subsidiaries associated companies including board directors chairman boards exchange company name listing information domicile share corporate governance sustainability committee regulationcomen capital equity interest listed finance serve respective capacities board homepublications report note roche group consolidated committees representatives shareholder significant financial statements list subsidiaries group pooled voting rights receive shareholdershtml associates remuneration set forth remuneration report finance report note major shareholders listed finance report roche group consolidated financial statements notes roche group consolidated related parties relationships financial statements equity attributable roche exist shareholders pooled voting rights shareholders related parties pages note financial statements roche crossshareholdings holding ltd significant shareholders addition significant shareholders published relevant webpage disclosure office six exchange regulation capital structure information roches capital structure provided form part share capital confer voting finance report notes financial rights nes confers rights one statements roche holding ltd share participate available earnings additional details contained articles liquidation proceeds following repayment share incorporation roche holding capital roches nes rights pertaining thereto including provisions protecting interests movement recognised amounts last three nes holders described articles financial years detailed finance report incorporation roche holding ltd notes financial statements roche holding ltd information debt instruments issued outstanding bonds provided company share capital chf finance report note roche group divided fully paid bearer shares consolidated financial statements debt nominal value chf restrictions exercise voting rights information employee stock options provided shares upon deposit shares voted without finance report note roche group restrictions consolidated financial statements equity compensation plans including detailed authorised conditional capital information stocksettled stock appreciation rights ssars plan restricted stock units addition nonvoting equity securities rsus plan performance share plan psp nes issued bearer form roche connect roche option plan httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche roche issued options apart employee neither options awarded employees stock options described finance report debt instruments issued note roche group consolidated financial effect roches share capital statements equity compensation plans options issued connection debt instruments board directors corporate executive committee information member board exception dr severin schwan none directors member corporate members board directors office executive committee listed pages end member roches corporate members board directors age limit executive committee served executive restriction term office capacity group subsidiary five financial years preceeding current reporting curricula vitae cvs current former period lack existing business members least last five years bodies connections group subsidiary independent information including information roches board directors independence definition years first election additional positions based definition swiss code best memberships activities available practice corporate governance economiesuisse continuously updated internet addition complemented specific preceding criteria status cvs bodies relevant see httpswwwrochecomaboutgovernanceboard reporting date december least last ofdirectorshtm five years separately available principles governance principles rules pursuant article para point vegv delegation competence reservation powers number permitted activities board management group companies directors corporate executive committee executive bodies company include economic members outlined articles environmental social topics principles incorporation roche holding ltd together internal organisation board directors division authority since annual general meeting elected responsibilities board management members board directors chairman remits board committees board directors members information control mechanisms available remuneration committee annual basis board dealings corporate management elections nominee voted separately governed bylaws see articles incorporation roche holding ltd minutes st annual board directors roche holding ltd general meeting roche holding ltd held organised ensure group conducts march businesses responsibly focus longterm httpswwwrochecomaboutgovernanceboardofdirectorshtm httpswwwrochecomaboutgovernanceexecutivecommitteehtm httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernanceannualgeneralmeetingshtm httpswwwrochecomaboutgovernancearticleofincorporationhtm board directors board committees board directors chairmans nomination committee board committees remuneration committee audit committee corporate governance sustainability committee corporate executive corporate executive committee committee value creation end roche board board directors established system delegated certain responsibilities several controls continuously monitored committees composition chairpersons audit committee corporate governance december described sustainability committee board committees authorities responsibilities directors consists following elements defined detail bylaws board report operating financial risks risk directors management system roche group established risk management committees chaired independent process covering entire company system directors place identify manage types risks potentially affecting business including economic according bylaws board directors environmental social impacts risks board meeting may convened without opportunities containing stakeholder input chairman present request board directors highest governance members roche board meets year body involved roches risk management policy sets assess chairmans performance meeting approach accompanying responsibilities attended chairman chaired pharmaceuticals diagnostics divisions vicechairman global functions conduct formal risk assessment process least year must develop risk part management information system plans material risks mis board directors regularly informed monitored deviations reviewed regular important issues sales performance performance dialogues consolidated group risk etc board access electronic information report including target risk profile discussed platform provides timely information corporate executive committee approved board directors boards committees together group business plan material system controls set forth risks reviewed board yearly basis httpswwwrochecomaboutgovernancecommitteeshtm httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche effectiveness risk management process evaluates appropriateness completeness monitored group risk advisory team efficiency processes controls action plans overall process regularly reviewed external implement necessary changes enhancements auditors findings presented audit developed together businessauditee committee full board details risk tracked completion management including risk factors risk statutory auditors see management policy see risk management chief compliance officer compliance officers website financial risk management specifically subsidiaries see described finance report safety health environmental protection system internal controls financial reporting department see pages finance report corporate sustainability committee internal audit science ethics advisory group seag group audit reports general counsel issues relating genetics genetic engineering direct access gives regular briefings audit committee corporate governance members corporate executive committee sustainability committee ongoing activities invited attend meetings board directors audit reports chief audit risk advisory report person agenda items executive attends audit committee partly concerning situation warrants corporate governance sustainability members enlarged corporate executive committee meetings external auditors committee may also invited attend board group audit independent appraisal function committees invite chairman board evaluates reviews groups activities corporate executive committee members deliver service board directors reports committee meetings may elect management annual audit plan yearly commission independent expert reports call defined focus areas eg market access thirdparty services consultants management validated senior management presented audit committee roche year several blackout periods imposed group committed maintaining high standard members board directors internal control throughout worldwide senior employees prohibited trading operations management responsible assessing company stock following blackout periods business risks aspects operation effect implementing effective efficient processes december january controls whilst ensuring compliance internal april april external rules regulations june july conducting operational audits group audit october october determines managements response risks blackout periods changed chairman surrounding business processes systems board directors circumstances warrant httpswwwrochecomsustainabilityapproachriskmanagementhtm additional information provided finance report note roche group consolidated financial statements risk management httpswwwrochecomsustainabilityenvironmenthtm httpswwwrochecomsustainabilityhtm httpswwwrochecomresearchanddevelopmentwhowearehowweworkethicsinrdethicalconflictshtm dr andreas oeri chairman corporate governance sustainability committee board directors met meetings board directors regularly conducts generally hours length including assessment selfassessmentassessment third fullday meeting addition day visit parties via electronical survey personal major subsidiary interviews performance board committees met follows members corporate executive committee chairmansnomination committee approx maximum ordinary notice period twelve hours months changeofcontrol clauses remuneration committee meetings approx employment contracts hours audit committee meetings approx hours management contracts fall within scope subsection annex corporate governance sustainability six directive information relating corporate committee meetings approx hours governance remuneration committee members recuse deliberations decisions matters affect interests figures indicate actual length meetings include directors extensive premeeting preparations postmeeting followup activitiescorporate governance roche attendance board board committee meetings corporate chairmans governance nomination remuneration audit sustainability board committee committee committee committee number meetings c franz hoffmann j bell j brown p bulcke h clevers member board since march hauser rp lifton oeri b poussot schwan c suessmuth dyckerhoff p r voser member board june member committee member since march member march member june remuneration shareholdings loans details regarding remuneration shareholdings rules aol loans content method determining content board cec compensation shareholding programmes rules principles basic principles elements compensation applicable performance shareholding programmes serving former related pay members board directors corporate rules principles executive committee together description allocation equity securities authorities procedure determining convertible rights options set forth separate remuneration report additional amount payments pages finance report members executive notes roche group consolidated committee appointed financial statements equity attributable roche vote pay general shareholders related parties pages meeting shareholders listed note financial statements rules loans credit facilities roche holding ltd board executive postemployment benefits shareholdings rules vote pay agm following rules remuneration shareholdings loans board directors board corporate executive committee cec set forth articles incorporation aoi httpswwwrochecomaboutgovernancearticleofincorporationhtm participatory rights shareholders participatory rights shareholders defined articles incorporation roches articles incorporation roche shareholders representing shares nominal value shares issued bearer restrictions least chf million request placement admission annual general meetings items agenda annual general meeting exception shares must deposited within must done later days specified period date meeting date meeting admittance card must issued shareholders name provided articles rules issue instructions incorporation shareholder elect independent proxy rules electronic represented third party annual general participation annual general meeting laid meeting corresponding invitation annual general meeting regulated articles articles incorporation contain restrictions incorporation exercise voting rights quorum requirements stipulated conformity swiss code obligations change control defensive measures articles incorporation contain provisions would terminated event acquisition mandatory bid rule swiss law applies vesting period restrictions preexisting awards would removed options could changeofcontrol clauses exercised immediately components remuneration based roche nes relationship statutory auditors annual general meeting roche holding ltd serving capacities provided march shareholders voted appoint statutory auditors participate kpmg ag kpmg statutory auditors audit committee meetings prepare written oral reports results audits based existing legal requirements swiss audit committee oversees assesses auditors code obligations article concerning makes recommendations board maximum term office seven years auditor information authorities responsibilities charge ian starkey auditorincharge since audit committee see article business year replaced mark baillache bylaws statutory auditors participated starting business year information four meetings audit committee long auditors auditorincharge httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernancearticleofincorporationhtmcorporate governance roche performance kpmg assessed based audit fee reviewed head group audit different elements affiliate surveys evaluate approved audit committee every year service level country level interviews takes consideration changes roches business roche key stakeholders selfevaluation well changes financial reporting audit kpmg internal processes ensure compliance standards regulations federal audit oversight authority faoa audit committee guide statutory auditors elected year annual general meeting kpmgs independence ensured limiting kpmg providing certain nonauditing services auditing services provided legally required furthermore permitted services exceed total audit fee auditors direct auditrelated services include assurance access audit committee chair well accounting services provided auditors head group audit discuss relevant issues necessarily provided statutory auditor services go beyond legal requirements reports statutory auditor could include attestation services comfort consolidated financial statements letters consents consultations financial statements found pages respectively finance report tax services include services respect compliance tax returns tax advice except kpmg received following remuneration services related audit tax services statutory auditors roche holding ltd auditors roche companies services include advice relating process including chugai improvements regulations trainings company formal policy governing millions chf engagement statutory auditor nonaudit auditing services services policy prohibits certain services auditrelated services provided permits certain services assurance limits agreed audit committee nonstatutory audits potential nonaudit service engagement reviewed tax services policy authority proceed services given total relationship independent proxy recent years bdo ag served independent compensation listed jointstock companies vegv proxy annual general meeting board directors appointed testaris ag march shareholders elected bdo ag replacement independent proxy conclusion independent proxy period general meeting board directors conclusion ordinary annual general nominates testaris ag election independent meeting shareholders bdo ag paid proxy general meeting period services annual general meeting conclusion ordinary according expenditure totalling chf general meeting shareholders chf rules issue instructions due bdo ags resignation july independent proxy rules electronic independent proxy elected general participation annual general meeting meeting view ceasing execution laid corresponding invitation mandates independent proxy pursuant annual general meeting regulated article para ordinance excessive articles incorporation information policy provided articles incorporation analyst investor conferences available corporate notices published swiss official internet publications available gazette commerce daily newspapers httpswwwrochecompublicationshtm designated board directors basler zeitung ordered email baselwarehouseservicesrochecom finanz und wirtschaft lagefi le temps neue fax zrcher zeitung contact address investor relations roche reports halfyear fullyear results f hoffmannla roche ltd investor relations business reports published print andor online group finance basel switzerland formats media events addition detailed tel firstquarter nine months sales figures fax published year april october current list publication dates available additional information including details specific english german internet contact persons available internet relevant information documents including media releases investor updates presentations httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecommediahtm httpswwwrochecominvestorshtm httpswwwrochecominvestorscontactshtmcorporate governance roche chief compliance officer compliance officers network chief compliance officer compliance addition roche established business ethics officers network committed ensuring incident reporting beir system enables roche group code conduct consistently chief compliance officer capture track complied throughout roche group monitor alleged violations initial reports also serves contact person shareholders local compliance officers resolution employees customers suppliers general public issues relating implementation business ethics incidents recorded system compliance code employees group internal investigation department parties become aware violations regionallocal management receives specific roche group code conduct bring concrete information alleged violation attention managers supervisors roche group code conduct one certain local compliance officer report chief predefined categories corporate governance compliance officer ms pascale schmidt email sustainability committee audit pascaleschmidtrochecom tel committee board directors informed disclosures treated confidentially substantial violations managements corrective addition end employees may actions made anonymously report irregularities complaints mother tongue via speakup line starting chief compliance officer reports general december new compliance tool group counsel also submits regular reports level socalled roche group code conduct corporate governance sustainability committee help advice line introduced strives needed audit committee board provide guidance case questions uncertainties directors interpretation roche group code conduct reference documents furthermore serve platform ideas suggestions concerning documents nonapplicabilitynegative disclosure expressly noted information negative declaration provided six swiss contained mentioned herein either non exchange corporate governance directive applicable omission construed commentary thereto httpswwwrochecomaboutgovernancecodeofconducthtm httpswwwrochecomsustainabilityapproachhtmremuneration report roche remuneration report employees compensated fairly transparently competitively participate appropriately companys success honour performance success optimal conditions enable employees make best possible contribution improving wellbeing people need principles www roche innovative agile company whose based transparent compensation structure compensation success depends substantially expertise ensure compensation packages competitive policy motivation performance employees structure individual components httpswwwroche conviction forms basis compensation policy regularly benchmarked swiss european comcareersfor international criteria remuneration guidelines employees roche aims remunerate employees fairly underlying principles also subject rewardshtm transparently line market conditions regular outside comparisons enable participate appropriately sound value companys success pursue goal providing however compensation policy one factor system competitive performancebased resultsoriented safeguarding roches future success key httpswwwroche compensation element corporate culture offers employees comcareersfor conditions make best employeesliving strive balanced mix fixed variable possible contribution shared corporate goal ourvalueshtm compensation components geared employees improving healthcare patients includes position management responsibility sound sustainabilityoriented value system based integrity courage passion firstly variable components intended create time decentralised management approach additional financial incentives achieve corporate plays major role wide scope individual goals keep innovation consistently high decisionmaking respectful interactions openness level increasing value company diversity wideranging training development creates stakeholder groups secondly order opportunities attractive working environment allow employees managers participate unidimensional diminishment questions companys business success adequate compensation remuneration would fall far short measures key objectives incentivised annual bonus payments longterm securities roche committed fair performancebased based programmes resultsoriented compensation policy links employees interests various global company like roche marketcompetitive stakeholder groups remuneration plays key role along performanceremuneration report roche remuneration decision process approval framework overview companies major swiss companies year remuneration committee roches reports findings full board external board directors decides remuneration board consulting firm pricewaterhousecoopers pwc members members groups corporate assists remuneration committee roche executive committee performing market comparisons advising pwc awarded additional mandates chairman group ceo members roche group information remuneration groups corporate executive committee must committees remit powers procedures present remuneration committee decides making remuneration decisions found corresponding compensation right bylaws roche board directors say decisions decision right reserved articles incorporation also outlined remuneration committee members sections principles governing specific remuneration components see remuneration committee tracks market data salaries leading global pharmaceutical remuneration decision process approval framework beneficiary remuneration board directors bod corporate executive decision approval components chairman c committee cec incl ceo roche group base payremuneration bonus c stocksettled stock remuneration committee appreciation rights ssars restricted stock units rsus annual general performance share plan psp board directors upon meeting expiring plans recommendation psp remuneration committee psp see end respectively decisions pension c remuneration committee end new psp awards board directors determined payment granted performance share plan psp expired psp must determine acting upon recommendations payment psp end remuneration committee end respectively see peer set abbott laboratories abbvie amgen astellas astrazeneca bayer bristolmyers squibb eli lilly glaxosmithkline johnson johnson merck co novartis pfizer sanofi takeda change composition peer set compared abb credit suisse lafargeholcim nestl sonova straumann swiss ubs zurich insurance httpswwwrochecomaboutgovernancearticleofincorporationhtm httpswwwrochecomaboutgovernancearticleofincorporationhtm since total aggregate amounts based general meeting shall vote annually decisions submitted general binding effect approval remuneration meeting approval implementing ordinance board directors resolved board excessive compensation listed jointstock directors corporate executive committee companies verordnung gegen bermssige verg tun details see gen bei brsenkotierten aktiengesellschaften vegv peer set abbott laboratories abbvie amgen astellas astrazeneca abb bayer credit suisse bristolmyers squibb roche lafargeholcim eli lilly nestl glaxosmithkline sonova johnson johnson straumann merck co swiss novartis ubs pfizer zurich insurance sanofi takeda peer set market comparison companies salary assessment pharma peer set major swiss companies procedure submitting total board retrospective approval executive remuneration shareholder approval total aggregate bonus amounts corporate annual general meeting executive committee chairman board year annual general meeting agm directors financial year ended shareholders approve total remuneration submitted retrospectively ordinary agm board directors corporate executive separate binding approval committee decided board directors remuneration committee board directors prospective approval respectively board executive aggregate remuneration submitted prospectively agm according approval agm separate binding approval period roche committed obtaining separate two ordinary agms binding shareholder approvals total remuneration paid board directors corporate executive committee followsremuneration report roche andr hoffmann chairman remuneration committee peer set approval total remuneration annual general meeting agm financial year financial year retrospective c chairman bod c bonus bonus financial year total amount cec corporate executive committee cec including ceo roche group bonus bonus financial year total amount prospective bod board directors bod including c base payremuneration aggregate total remuneration agm agm base payremuneration corporate executive committee cec including ceo roche group cec aggregate total remuneration agm agm base pay ssars base pay rsus stocksettled stock appreciation rights ssars indirect benefits restricted stock units rsus indirect benefits agm agm agm remuneration components overview remuneration elements composed ssars rsus already described outlook based already existing individual target value annual report starting total lti corporate executive committee composition remuneration components members base pay measured longterm incentive lti corporate january year vesting expiration periods executive committee enlarged corporate aligned newly issued ssars rsus executive committee changed see unlike participants two programmes members corporate executive lti corporate executive committee committee choice determining mix enlarged corporate executive committee rsus ssars fouryear complemented restricted stock units rsus cliff vesting corporate executive committee lti mix ssarsrsus fixed base calculation vesting period cliff vesting expiration period based already existing new years new years new years ssars individual target value years years years total lti corporate executive committee members rsus base pay measured new years new years january year remaining participants ssars expiration period newly issued ssars rsus programmes offered yearly basis extended currently seven years ten years choice three combinations determine mix gives participants additional three years restricted stock units rsus stocksettled stock exercise vested ssars vesting schedule appreciation rights ssars options used instead newly issued rsus changed threeyear cliff ssars countries following options vesting fouryear annual vesting year available granted rsus vest become available participants vesting schedule ssars choice choice choice currently threeyear annual vesting also aligned ssars ssars ssars fouryear annual vesting schedule rsus rsus rsus new grants offering level choice empowers participants changes make roche long term incentive engage fully total rewards enables programme attractive enabling roche attract better understand critical element motivate retain best talent keep aligned compensation increases value programme companys longterm success positions roche first among peer group provide benefitremuneration report roche therefore remuneration remuneration components linked members board directors corporate employees performance companys financial executive committee composed following performance commercial success thus align elements concrete composition see chart interests roche employees composition remuneration board shareholders directors corporate executive committee lti remuneration components intended fixed base salary complemented annual sustainably homogenously longterm variable bonus shortterm incentive sti oriented perspective align managements interest perennial remuneration elements ssars rsus shareholders holders nonvoting longterm incentive lti equity securities give participating managers additional incentive achieve sustainable since end new performance shareholder value growth share plan psp awards granted acting upon recommendations remuneration committee end board directors determined payment expired psp must determine payment psp end respectively composition remuneration board directors corporate executive committee annual remuneration elements description c bod ceo roche group cec base pay monthly payment q uarterly remuneration see payments bonus annual payment years years cash see blocked nonvoting blocked nonvoting equity securities equity securities andor shares andor shares pensions etc see perennial remuneration elements stocksettled stock see appreciation rights ssars restricted stock see units rsus performance share see years plan psp blocked nonvoting expiring plans equity securities psp andor shares psp variable longterm sti base salary bonus indirect benefits employer contribution lti pensions insurance contributions stocksettled stock appreciation rights roche roche connect restricted stock units tax consulting services remuneration performance share plan components expense allowances others childrens schooling costs foreign tax obligation ahvivalv fixed base pay fixed qualitative individual functional performance base pay cash payment determined objectives competitive reasons roche position based salary market data leading disclose individual performance objectives global pharmaceutical companies see footnote members corporate executive committee major swiss companies see footnote chairman reflects individuals abilities experience performance time pay adjustments likewise december end reporting year linked individual performance take january following reporting year remuneration account prevailing market conditions committee decides bonuses amounts companys overall financial situation payable chairman board members corporate executive committee respect remuneration committee makes reviews current reporting year based performance final decision individual base pay paid aforementioned objectives chairman board directors members time remuneration committee also decides corporate executive committee form bonuses awarded ie cash payments remuneration members board andor nonvoting equity securities andor shares bonuses variable remuneration committee uses complete bonuses annually awarded individual discretion weighting criteria contributions value creation business year bonus allocation meant incentive strive outstanding results create new business opportunities stocksettled stock appreciation rights bonus amounts linked group divisional ssars longterm core profits sales growth constant exchange rates ssars proportion lti operating profit capital charge opac based corporate executive committee composed core operating profit core earnings per share based already existing individual target value nonvoting equity security nes growth constant total lti corporate executive committee exchange rates product development pipeline members base pay measured diversity employees managers environmental january year goals achievement measurable andremuneration report roche ssars entitle holders benefit financially performance share plan psp longterm increase value roches nonvoting equity psp established periods three securities grant date exercise years based threeyear comparison date ssars granted vest together total shareholder return tsr peer four years exercised within ten companies see footnote respective year years grant date unexercised ssars lapse psp consisted three overlapping performance without compensation since fair value cycles new cycle starting beginning ssars calculated grant date using year cycle finishing end year trinomial model american call options details plans key performance metric award see tsr calculated threemonth moving average rate start end ssars corporate executive committee performance cycle allocated individually remuneration committees discretion total around new psp awards granted since end employees received ssars therefore two overlapping performance cycles psp restricted stock units rsus longterm psp psp closed proportion restricted stock units december see rsus members corporate executive committee total lti based board directors acting upon recommendations already existing individual target value total remuneration committee must determine lti corporate executive committee members payment ongoing psp end base pay measured january using complete discretion year rsu awards allocated individually corporate executive committee remuneration indirect benefits committees discretion shown ceo roche group chairman respectively members rsus contain rights receive nonvoting equity corporate executive committee additionally securities andor shares since newly received indirect benefits payments pension funds defined fouryear vesting period plus value insurances roche connect payments foreign adjustment amount equivalent tax obligation tax consulting services annual sum dividend paid vesting period expense allowances shown individual attributable number nonvoting equity members corporate executive committee securities andor shares individual award received payments family children education granted vested recipient allowance schooling costs children corporate executive committee four years thereafter resulting nonvoting equity securities andor shares may remain blocked ten years rsus serve remuneration component around eligible roche employees weighting fixedvariable longterm remuneration components target percentage total remuneration chairman board directors corporate executive committee including ceo roche group fixed variable longterm variable longterm remuneration paid members corporate executive committee ranged fixed compensation ratio variable remuneration components relative fixed base pay corporate executive committee ratio variable remuneration components bonuses ssars rsus relative value fixed base pay lti longterm sti variable total criteria bonus ssars total lti rsus total lti individual target value minimum maximum performance criteria group objectives group divisional value development determined value development determined business performance individual performance nes performance plus value objectives considering core profits grant adjustment dividends sales growth constant exchange nes grant rates operating profit capital charge opac based core operating profit core earnings per share nonvoting equity security nes growth constant exchange rates product development pipeline diversity employees managers environmental goals split group objectives na na b individual objectives na na weighting criteria complete discretion remunertion committee decision objectives na applicable assessed consideration performance competitors macroeconomic development b ased already existing individual target value total lti corporate executive committee members base pay measured january year details please refer following sections remuneration report see also finance report note roche group consolidated financial statements related parties note financial statements roche holding ltd board executive shareholdings remuneration report roche remuneration board directors resolution approval directors table board remuneration chairman board activities roche paid legally required employers directors members board directors contributions total chf swiss social decided remuneration committees security programmes providing retirement disability discretion taking account market comparisons unemployment benefits ahvivalv members board directors beside legally remuneration form cash payments required contributions separately stated annually tracked market data directors chairman board directors pay leading global pharmaceutical companies see footnote major swiss companies basic remuneration board directors see footnote assisted consultancy excluding chairman remained unchanged pwc since previous years board exception chairman board directors separately submit total aggregate directors bonus form blocked shares bonus chairman board directors dr severin schwan executive member general meeting financial year board members board directors retrospectively binding approval awarded shares nonvoting equity securities ssars maximum amounts total aggregate remuneration board directors period loans credits granted members ordinary general meeting board directors ordinary general meeting separately tabled previous years general capacity member chugai meetings prospectively binding approval see international council cic chugai pharmaceutical co ltd andr hoffmann received honoraria amount remuneration members amounting total usd chf board directors members board directors advisory service genentech scientific received remuneration additional compensation review board prof dr richard p lifton received form quarterly fixed cash payments shown honoraria amounting total usd remuneration members board chf list members positions committee memberships chairmanships see detidua remuneration members board directors chf additional remuneration additional special basic remuneration committee memberschairs remuneration total remuneration c franz chairman see total remuneration paid chairman board directors hoffmann vicechairman see j bell j brown p bulcke h clevers since march hauser rp lifton see oeri b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff pr voser end june total exception members chairmans committee chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board prorated remuneration period march december prorated remuneration period january end june additionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration detiduaremuneration report roche remuneration members board directors chf additional remuneration additional special basic remuneration committee memberschairs remuneration total remuneration c franz chairman see total remuneration paid chairman board directors hoffmann vicechairman j bell j brown p bulcke hauser rp lifton oeri b poussot schwan see highest total remuneration paid dr severin schwan member corporate executive committee remuneration received primary function ceo roche group reflected total remuneration corporate executive committee c suessmuth dyckerhoff pr voser total w ith exception members chairmans committee chairman vicechairman board members receive chf year committee serve chf year committee chair remuneration serving vicechairman board additionally employer contribution ahvivalv totalling chf including chairman paid form part remuneration total remuneration paid chairman form shares blocked ten years payable board directors march put shareholder binding vote chairman dr christoph franz received total ordinary annual general meeting agm remuneration shown remuneration committees bonus proposal adopted chairmans total remuneration contained late respect financial year total remuneration board directors total remuneration paid chairman board directors chf base salary cash bonus subject approval annual general meeting pension fundsmgb insurancesannual expense allowances total form shares blocked years calculation number shares based price date transfer march respectively approval agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm respectively ncluding employer contribution social securities beneficial parts mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits dissolved dditionally employer contribution ahvivalv chf chf paid form part remuneration detidua detidua total remuneration paid board board remuneration subject approval directors annual general meeting calendar year members board directors received remuneration including submission chairmans total aggregate bonuses employer contribution social bonus binding vote annual general securities beneficial parts totalling chf meeting chf excluding additional remuneration chairman board employers contribution paid ahvivalv directors includes bonus award chf totalling chf chf form shares blocked ten years shown form part remuneration table section total remuneration paid chairman board directors board remuneration paid former members directors submit remuneration committees board directors bonus proposal adopted late former member board directors dr franz chairman board dr christoph franz b humer received fees amounting total respect financial year payable march usd chf serving member excluding legally required employers chugai international council cic chugai contributions ahvivalv shareholder pharmaceutical co ltd binding vote ordinary annual general meeting former member board directors william burns received honoraria amounting total usd chf capacity member chugai international council cic chugai pharmaceutical co ltd additional remuneration paid retrospective approvals chairmans total aggregate bonus chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv bonus award form shares blocked years calculation number shares based price date transfer march march april respectively approval agm agm agm respectively calculation value consideration reduction value due blocking period years reduced market value submitted shareholder approval agm approved agm agm respectively detiduaremuneration report roche submission boards total aggregate dr severin schwans remuneration shown future remuneration binding shareholder vote receives function ceo roche board directors proposes group member corporate executive ordinary agm approve board remuneration totalling committee included part chf excluding legally corporate executive committees total remuneration required employers contributions ahvivalv excluding bonuses period ending ordinary agm prospective approvals boards total aggregate future remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonuses reconciliation reported remuneration comparison ordinary agm shareholders approved remuneration ordinary agm actual remuneration amounted members board directors chf excluding legally required employers ordinary agm approved board remuneration contributions ahvivalv excluding bonuses totalling chf excluding legally required employers contributions ahviv alv excluding bonuses period ending ordinary agm prospectively approved total remuneration members board directors comparison actual total payments made chf total remuneration total remuneration total remuneration period period period agm agm agm agm agm agm maximum total remuneration approved agm actual total remuneration paid calculation end period within approved limit calculation end period yes yes excluding legally required employers contributions ahvivalv excluding bonuses security holdings related parties note directors andr hoffmann dr andreas oeri financial statements roche holding ltd members founders families closely significant shareholders addition associated belong contractually bound december december shareholder group pooled voting rights respectively members board directors end group held shares persons closely associated held roche issued shares detailed information shares nonvoting equity securities nes group found finance report note american depositary receipts adrs shown roche group consolidated financial statements table security holdings security holdings shares nes december december nonvoting nonvoting equity close relatives equity close relatives securities security securities security shares nes holdings others shares nes holdings others number number numbertype number number number numbertype number board directors c franz hoffmann j bell j brown p bulcke h clevers na na na na hauser nes nes rp lifton adrs adrs oeri b poussot schwan see security holdings see security holdings corporate executive committee corporate executive committee c suessmuth dyckerhoff total nes adrs nes adrs na applicable shares held shareholder group pooled voting rights listed jointly held close relative roches adr american depositary receipt listed otcqx httpswwwotcmarketscomstockrhhbyquote international premier symbol rhhby isin us traded usd eight adrs represent one underlying nesremuneration report roche remuneration corporate executive committee resolution approval members corporate executive remuneration members corporate committee received remuneration work executive committee decided shown amount remuneration remuneration committees discretion taking ceo roche group dr severin schwan account market comparisons explained detail previous years board payments daniel oday retired directors separately submit total aggregate corporate executive committee end bonuses corporate executive committee december roche end general meeting financial year february included aggregated retrospectively binding approval total remuneration corporate executive committee see maximum amounts total aggregate remuneration corporate executive committee payments dr michael heuer ceo roche period ordinary general meeting diagnostics retired member ordinary general meeting corporate executive committee retired tabled previous years general roche july included aggregated meetings prospectively binding approval see total remuneration corporate executive committee see amount remuneration members corporate executive committee individually specified remuneration dr thomas general provisions assigning authority decisions schinecker include payments former corporate executive committee remuneration role well payments member corporate remuneration committee board executive committee august directors outlined remuneration decision process approval framework highest total remuneration paid dr severin schwan member corporate executive committee chf base salary ssars pension fundsmgb insurances roche connect bonus subject approval total aggregate bonuses corporate executive committee annual general meeting blocked shares rsus na psp na payments incl expense allowancefor tax consulting services total na applicable calculation value nonvoting equity securitiesshares consideration reduction value due blocking period years reduced market value including employer contribution social securities beneficial parts detailed calculation remuneration see annual report number ssars grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee ssars blocked years may thereafter exercised whilst exercising resulting nes automatically blocked additional years calculation value nonvoting equity securities consideration reduction value due additional blocking period years reduced market value number ssars grant value according trinomial model american call options chf trinomial model american call options value described stocksettled stock appreciation rights ssars members corporate executive committee mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits dissolved hares blocked years calculation number shares based share price date transfer march approval agm c alculation rsus value number rsus multiplied grant value chf nes closing price grant date march per rsu arget number nonvoting equity securities psp nonvoting equity securities multiplied per nonvoting equity securities price averaged three months october december prior start performance cycle chf nonvoting equity security includes annual expense allowance chf payments tax consulting services chf chf family children education allowance chf anniversary payment chf additionally employer contribution ahvivalv chf chf paid form part remuneration detidua highest total remuneration paid highest total remuneration paid member dr severin schwan member corporate corporate executive committee see executive committee included total amount paid corporate dr severin schwan executive member board executive committee see total remuneration directors received remuneration primary paid members corporate executive function ceo roche group reflected committee remuneration report roche allocation dr michael heuer bonus chf proposed included aggregated total remuneration corporate executive committee see total aggregate amount bonuses brought forward binding vote annual general meeting daniel oday received bonus payment except dr severin schwan members corporate executive committee receive bonus cash payment due march dr severin schwan receive bonus form roche shares blocked ten years see bonus payment due march bonus chf subject approval total aggregate bonuses corporate executive committee annual general meeting b anderson na hippe g keller schinecker na c wilbur total na applicable detidua base pay members corporate executive committee base pay chf b anderson na hippe g keller schinecker na c wilbur total na applicable detidua payments daniel oday dr michael heuer retirement roche end february july respectively included aggregated total remuneration corporate executive committee see bonuses members corporate executive committee remuneration committee board directors determined corporate executive committee members bonuses based performance agreed objectives remuneration committee uses complete discretion weighting criteria bonus detidua stocksettled stock appreciation rights total lti corporate executive committee ssars members corporate members base pay measured executive committee january year ssars corporate executive committee allocated individually remuneration fair value ssars calculated grant committees discretion ssars shown date using trinomial model american call ssars table entitle holders options trinomial model effective method benefit financially increase value valuation american call options considers roches nonvoting equity securities nes possibility exercising option time prior grant date exercise date strike price maturity called american option compared ssars terms multiyear plan european option allows exercise closing price roche nes grant date maturity date ssars vest four previously granted ssars three years grant date vested numbers ssars strike prices expiry dates ssars exercised converted nes within grant values ssars shown ten previously granted ssars within seven years ssars table numbers ssars grant date unexercised ssars lapse without calculated time issue entered compensation values table ssars proportion lti ssars granted daniel oday corporate executive committee composed dr michael heuer based already existing individual target value stocksettled stock appreciation rights ssars chf ssars ssars b anderson na hippe g keller schinecker na c wilbur total na applicable information trinomial model american call options please refer boyle phelim p lattice framework option pricing two state variables journal financial quantitative analysis volume issue mar httpswwwrochecomdam jcraaacbfabcbeacentrinomialmodelpdf see strike prices table ssars remuneration report roche restricted stock units rsus defined fouryear vesting period plus value members corporate executive committee adjustment amount equivalent proportion restricted stock units sum dividend paid vesting period rsus members corporate executive attributable number nonvoting equity committee composed total lti securities andor shares individual award based already existing individual target value granted vested recipient total lti corporate executive committee corporate executive committee four members base pay measured years thereafter resulting nonvoting equity january year rsu awards allocated securities andor shares may remain blocked individually corporate executive committee ten years remuneration committees discretion daniel oday dr michael heuer rsus contain rights receive nonvoting equity received rsus securities andor shares since newly restricted stock units rsus number value grant chf value chf b anderson hippe g keller schinecker c wilbur total na applicable calculation value consideration reduction value due additional blocking period years reduced market value c alculation value consideration reduction value due additional blocking period years reduced market value performance share plan psp since end new psp awards members corporate executive committee granted therefore two psp established periods three overlapping performance cycles psp years based threeyear comparison psp psp closed total shareholder return tsr peer december board directors acting companies see footnote respective year upon recommendations remuneration psp consisted three overlapping performance committee must determine payment cycles new cycle starting beginning ongoing psp end using year cycle finishing end year complete discretion plans key performance metric award tsr calculated threemonth moving average provisions plan number rate start end nonvoting equity securities nes shares performance cycle reserved participants cycle detidua number securities actually awarded award granted requires roche depend whether extent investment securities perform well better roche securities shares nes outperforms peer set event investment average return investment securities issued roche securities underperforms average return set peer companies comparisons based delivered peer companies fewer nes securities market prices dividend yields shares awarded ie total shareholder return tsr reduce effect shortterm market fluctuations security end psp cycle based prices averaged three months october threemonth average distributed dividends december prior start performance cycle totalling chf billion chf billion three months october december chf billion chf billion end cycle according terms plan participants received originally targeted nes awarded roche securities perform better average end psp cycle nes peer set board directors elect originally targeted nes incl nes increase nes shares award maximum group ceo outlined pages award double originallevel reserved target annual report taking account retired number nes shares according psp plus members corporate executive committee value adjustment amount equivalent awarded sum dividend paid vesting period attributable number nonvoting bill anderson dr thomas schinecker dr michael equity securities shares individual heuer participating psp programme performance share plan psp fair value grant per nonvoting equity security nes nes prices averaged three months october december target number nonvoting prior start fair value target number equity securities nes performance cycle nonvoting equity securities psp psp nes psp number value chf value chf hippe ga keller shares c wilbur nes reserved total psp calculation value nonvoting equity securities consideration reduction value due blocking period years reduced market value ee footnote remuneration report roche detidua detidua indirect benefits employer contributions chf payments pension payments pension annual taxtax funds annual taxtax funds expense roche consulting mgb expense roche consulting insurances allowances connect services insurances allowances connect services b anderson na na na na hippe g keller schinecker na na na na c wilbur total na applicable including employer contribution social securities beneficial parts mgb stiftung der f hoffmannla roche ag fr mitarbeitergewinnbeteiligung employee profitsharing foundation supplementing occupational pension benefits dissolved remuneration loans members loans credits granted corporate executive committee members corporate executive committee based legal contractual obligations roche paid individual members corporate maximum regular period notice members executive committee costs respect temporary corporate executive committee months relocation housing family children changeofcontrol clauses education allowance childrens schooling employment contracts costs totalling chf aforementioned additional payments included total remuneration members corporate executive committee detidua indirect benefits members addition members corporate executive corporate executive committee committee received annual expense allowances employer contributions made social security members payments foreign tax obligations schemes pension plans groupwide employee tax consulting services shown table stock purchase plan roche connect respect members corporate executive committee shown indirect benefits employer contributions payments employer contibutions indirect benefits table table daniel oday dr michael heuer retirement roche end february roche connect voluntary stock purchase plan july respectively included aggregated offering employees opportunity buy roche total remuneration corporate executive nonvoting equity securities nes amount committee see equal annual salary discount nes purchased plan subject holding period four years switzerland remuneration former members chf chf corporate executive committee form part remuneration pensions totalling chf chf paid former corporate additional remuneration executive committee members pension mentioned payments paid current former benefits guaranteed various former members corporate executive committee members executive committee widows outside pension fund pledged executive remuneration subject approval due gaps pension provision resulting annual general meeting postings abroad instance transferred roche pension fund required oneoff submission executive total aggregate transfer chf pension fund bonuses binding vote annual general meeting total remuneration paid members board directors proposes awarding members corporate executive committee corporate executive committee bonuses calendar year members dr severin schwan form roche shares corporate executive committee received remuneration blocked ten years members including bonuses employer contribution corporate executive committee cash social securities beneficial parts payments payment see totalling chf respect dr michael heuer ceo roche diagnostics financial year chf retirement end july payments excluding legally required employers contributions daniel odays retirement roche ahvivalv submit proposed total end february totalling chf amount ordinary annual general meeting excluding additional employers agm binding vote contribution paid ahvivalv totalling retrospective approvals members executive committees total aggregate bonuses chf proposal agm agm agm aggregate amount aggregate amount aggregate amount financial year financial year financial year total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv detidua detidua detiduaremuneration report roche submission executive total future aggregate incentives ssars calculated grant value without remuneration binding shareholder vote considering reductions value due blocking board directors proposes periods applicable rsus see calculated ordinary agm approves remuneration time reservation nonvoting equity securities corporate executive committee totalling shares without considering reductions value due chf excluding legally required blocking periods contributions pension benefits employers contributions ahvivalv excluding legally required employers contributions excluding bonuses period ending ahvivalv well contributions expenses ordinary agm payments foreign tax obligations tax consulting services roche connect amount executive total future aggregate remuneration composed base pay longterm prospective approvals members executive committees total future aggregate remuneration chf proposal agm agm agm aggregate amount aggregate amount aggregate amount period period period agm agm agm agm agm agm total aggregate amount proposal approval approved agm excluding legally required employers contributions ahvivalv excluding bonuses reconciliation reported remuneration excluding bonuses period ending shareholders prospectively approved ordinary agm remuneration members corporate executive committee comparison ordinary agm ordinary agm approved remuneration ordinary agm remuneration amounted corporate executive committee totalling chf excluding legally required employers chf excluding legally required contributions ahvivalv excluding bonuses employers contributions ahvivalv psp assumption maximum value prospectively approved total remuneration members executive committee comparison actual total remuneration effected chf amount period amount period amount period agm agm agm agm agm agm maximum total remuneration prospectively approved agm total remuneration calculated end calculation end corresponding agmagm period period agm agm actual total remuneration realised corresponding agmagm period based actual amount calculated restrospectively calculation end corresponding psp cycle calculation end end end grant value rsus period agm agm psp cycle within approved limit calculation end period calculation end period yes additional amount paid new members corporate executive committee approval agm within approved total amount excluding legally required employers contributions ahvivalv excluding bonuses ncluding assumption amount maximum possible award sharesnonvoting equity securities corresponding psp cycle ue award nes psp cycle originally included calculation maximum possible award amount total remuneration period agm agm reduced chf clawback activity leading serious disciplinary action addition applicable statutory provisions roches repeated willful failure perform duties longterm incentive plans include option reasonably assigned roche partially reclaim distributed compensation result violation law public regulation special circumstances clawback commission crime gross negligence willful misconduct employee voluntarily serves notice employment termination employment ssars see engaging conduct bringing disgrace disrepute rsus see unvested date roche andor subsidiaries termination employment lapse immediately violation roches directives guidelines without compensation relating business conduct upon termination employment result according regulations psp programme serious misconduct ssars rsus granted originally targeted awarded nes shares outstanding whether vested unvested shall lapse shall lapse without compensation upon notice immediately without compensation according termination employment given reason ssars plan rules serious misconduct redundancy disability retirement participant may include inter aliaremuneration report roche guidelines security holdings long serve corporate executive board directors decided ceo committee exception bill anderson roche group members corporate dr thomas schinecker joined corporate executive committee must acquire shares andor executive committee must fulfil nes equivalent two annual base salaries ceo requirement end members roche group since equivalent five annual base corporate executive committee fulfil salaries one annual base salary respectively requirement end retain holdings type security value acquired ceo roche group shares andor nes annual base salary members corporate executive committee shares andor nes annual base salary security holdings december december respectively members corporate executive committee persons closely associated held securities shown following tables shares nonvoting equity securities nes ssars shares nonvoting equity securities nes december december close relatives close relatives shares nes security holdings shares nes security holdings number number numbertype number number numbertype corporate executive committee shares nes shares nes schwan b anderson na na na na hippe ga keller schinecker na na na na c wilbur total na applicable ssars number ssars held december corporate executive committee schwan b anderson hippe g keller schinecker ca wilbur total price chf market price per nes december chf expiry date grant value per ssar chf since trinomial model american call options v alues according corresponding annual reports restricted stock units rsus number rsus held december corporate executive committee schwan na na b anderson hippe na na g keller na na schinecker c wilbur na na total grant value per rsu chf chf chf nes closing price grant nes closing price grant nes closing price grant date march date march date march statutory auditors report roche general meeting roche holding ltd basel audited accompanying remuneration audit involves performing procedures obtain audit report roche holding ltd year ended evidence disclosures made remuneration december audit limited report regard compensation loans credits information according articles accordance articles ordinance ordinance excessive compensation listed procedures selected depend auditors jointstock companies ordinance contained judgement including assessment risks sections marked audited grey line including material misstatements remuneration report respective footnotes pages whether due fraud error audit also includes remuneration report evaluating reasonableness methods applied value components remuneration well assessing overall presentation remuneration responsibility board directors report board directors responsible preparation overall fair presentation believe audit evidence obtained remuneration report accordance swiss law sufficient appropriate provide basis ordinance board directors also opinion responsible designing remuneration system defining individual remuneration packages opinion opinion remuneration report year auditors responsibility ended december roche holding ltd responsibility express opinion complies swiss law articles accompanying remuneration report conducted ordinance audit accordance swiss auditing standards standards require comply ethical requirements plan perform audit obtain reasonable assurance whether remuneration report complies swiss law articles ordinance kpmg ag mark baillache marc ziegler licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved independent assurance report nonfinancial reporting corporate governance sustainability committee roche holding ag basel engaged perform assurance procedures provide roche group internal nonfinancial reporting guidelines based assurance aspects nonfinancial reporting responsible care health safety environmental roche holding ag basel consolidated subsidiaries protection reporting guidelines published european roche included annual report report chemical industry council cefic gri standards published october global reporting initiative gri scope subject matter roche group internal corporate reporting manual assurance engagement reasonable limited levels sustainability reporting guidanceeconomic performance assurance focused data information year ended issued june december disclosed report roche roche materiality determination process group level based gri standards published october global carried work data reported prior reporting initiative gri reporting periods respect projections targets defined guidelines payments donations people contributions key figures sustainability risks reasonable assurance opportunities internally gathered collated aggregated following data information published report within scope reasonable assurance engagement inherent limitations key figures related grants donations patient accuracy completeness nonfinancial indicators organisations grants donations healthcare organisations subject inherent limitations given nature methods sponsorships healthcare patient organisations determining calculating estimating data assurance material aspects disclosed report together report therefore read connection roches contributions key figures guidelines definitions procedures nonfinancial reporting management reporting processes respect performance contributions key figures well related control environment relation data aggregation contributions key roches responsibility figures roche corporate governance sustainability committee responsible subject matter criteria well limited assurance selection preparation presentation selected information following data information published report accordance criteria responsibility includes within scope limited assurance engagement design implementation maintenance related internal control materiality determination process roche group level relevant reporting process free material according requirements gri standards misstatement whether due fraud error disclosed report design sustainability risks opportunities responsibility determination process based roche group level activities responsibility perform limited reasonable assurance disclosed paragraph risk management engagement express conclusions aspects report nonfinancial reporting roche planned performed people key figures disclosed pages report procedures accordance international standard safety security health environmental protection assurance engagements isae revised assurance key figures including greenhouse gas emissions engagements audits reviews historical financial scope scope resulting business flights information respect greenhouse gas emissions tables graphs pages report international standard assurance engagements isae figures roche group level relation payments assurance engagements greenhouse gas statements issued donations disclosed report international auditing assurance standards board management reporting processes respect people standards require plan perform assurance payments donations key figures well related engagement obtain limited reasonable assurance control environment relation data aggregation identified nonfinancial information prepared material aspects key figures accordance roches policies procedures well management reporting processes together related criteria control environment relation data aggregation exist management reporting processes respect non designed form appropriate basis reporting well financial reporting key figures prepared roche based give fair picture nonfinancial performance roche policies procedures set forth following roche group guideline grants donations sponsorship limited assurance engagement substantially less scope gsd data collection process disclosed website reasonable assurance engagement relation pricewaterhousecoopers ag birchstrasse postfach ch zurich telephone telefax wwwpwcch pricewaterhousecoopers ag member global pricewaterhousecoopers network firms separate independent legal entityindependent assurance report roche risk assessment procedures including understanding internal key organisational values objectives report prioritisation control procedures performed response assessed material aspects risks consequently nature timing extent procedures inspecting integration sustainability risks gathering sufficient appropriate evidence deliberately limited opportunities group risk management process relative reasonable assurance engagement therefore less adherence internal guidelines assurance obtained limited assurance engagement assessment processes data consolidation reasonable assurance engagement procedures selected reviewing management nonfinancial reporting processes depend assurance practitioners judgement payments donations contributions people key figures independence quality controls assessing aggregation process data roche group level complied independence ethical requirements code ethics professional accountants conducted work data outlined issued international ethics standards board accountants subject matter defined believe evidence founded fundamental principles integrity objectivity obtained sufficient appropriate provide basis professional competence due care confidentiality assurance conclusions professional behaviour reasonable assurance conclusion firm applies international standard quality control based work performed opinion following applies accordingly maintains comprehensive system quality control material aspects including documented policies procedures regarding compliance contributions key figures described scope ethical requirements professional standards applicable subject matter section material aspects stated legal regulatory requirements accordance reporting criteria b management reporting processes respect summary work performed contributions key figures well control environment assurance procedures included amongst others following relation data aggregation contributions key work figures working designed provide appropriate review application roche group guidelines basis reporting reviewing application roche group nonfinancial c contributions key figures give fair picture non reporting contributions guidelines financial performance roche site visits management inquiry visiting selected sites roches pharmaceuticals limited assurance conclusion diagnostics divisions usa norway china hong kong based work performed nothing come attention selection based quantitative qualitative criteria causing us believe material aspects interviewing personnel responsible internal nonfinancial roche materiality determination process group level reporting data collection sites visited disclosed adhere principles guiding roche group level determine understanding application factors eg soundness stakeholder determination peer roches nonfinancial contributions guidelines review relevance regulatory environment integration assessment key figures key organisational values objectives defined performing tests sample basis evidence supporting gri standards selected payments donations contributions people design sustainability risks opportunities key figures eg roche accident rate energy consumption determination process group level disclosed emissions air water usage discharge grants donations function designed patient organisations employee engagement rate women key figures mentioned scope subject matter key leadership roles concerning completeness accuracy section disclosed within nonfinancial reporting adequacy consistency roche annual report stated accordance review documentation analysis relevant policies reporting criteria principles management reporting processes collect reviewing relevant documentation sample basis including aggregate payments donations people key roche group nonfinancial reporting policies management figures well control environment relation reporting structures documentation data aggregation work exist designed reviewing principles roche materiality process providing definition development adherence pricewaterhousecoopers ag gris environmental social economic reporting requirements addressing soundness identification process christophe bourgoin fabienne fricker determination impacted stakeholders peer competition review integration relevant regulatory requirements integration zurich january key dates published f hoffmannla roche ltd annual general meeting group communications march basel switzerland tel firstquarter sales wwwrochecom april orderdownload publications halfyear results internet rochecompublications july email baselwarehouseservicesrochecom fax ninemonth sales october media relations tel email mediarelationsrochecom investor relations tel email investorrelationsrochecom corporate sustainability committee tel email corporatesustainabilityrochecomimprint roche cautionary statement regarding forwardlooking statement regarding earnings per share growth statements profit forecast interpreted annual report contains certain forwardlooking mean roches earnings earnings per share statements forwardlooking statements may subsequent period necessarily identified words believes expects match exceed historical published earnings anticipates projects intends seeks earnings per share roche estimates future similar expressions discussion among things strategy goals trademarks legally protected plans intentions various factors may cause actual results differ materially future links thirdparty pages provided convenience reflected forwardlooking statements contained express opinion content annual report pricing product thirdparty pages expressly disclaim initiatives competitors legislative regulatory liability thirdparty information use developments economic conditions delay thereof inability obtaining regulatory approvals bringing products market fluctuations currency roche annual report published german exchange rates general financial market english conditions uncertainties discovery development marketing new products new reporting consists actual annual report uses existing products including without limitation finance report contains annual negative results clinical trials research projects financial statements consolidated financial unexpected side effects pipeline marketed statements regards content management products increased government pricing pressures report per articles incorporation consists interruptions production loss inability aforementioned reports exception obtain adequate protection intellectual property remuneration report rights litigation loss key executives employees adverse publicity printed nonchlorine bleached fsccertified paper news coverageour images videos f hoffmannla roche ltd basel switzerland would like immediately experience patient stories words get free xtend app trademarks legally protected open scan option app look icon watch videos wwwrochecom ios android